

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**
Washington, D.C. 20549

FORM 10-Q

(Mark One)

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended: **June 30, 2023**

Or

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission file number 1-37654

Fortive Corporation

(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction of
incorporation or organization)

47-5654583
(I.R.S. employer
identification number)

6920 Seaway Blvd
Everett, WA
(Address of principal executive offices)

98203
(Zip code)

Registrant's telephone number, including area code: **(425) 446-5000**

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading symbol	Name of each exchange on which registered
Common stock, par value \$0.01 per share	FTV	New York Stock Exchange

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 (the "Exchange Act") during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer
Non-accelerated filer

Accelerated filer
Smaller reporting company
Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Indicate by check mark whether the registrant is a shell company (as defined by Rule 12b-2 of the Exchange Act). Yes No

The number of shares of common stock outstanding at July 21, 2023 was 352,024,375.

FORTIVE CORPORATION

INDEX

FORM 10-Q

		<u>Page</u>
PART I -	FINANCIAL INFORMATION	
Item 1.	Financial Statements	
	Consolidated Condensed Balance Sheets	4
	Consolidated Condensed Statements of Earnings	5
	Consolidated Condensed Statements of Comprehensive Income	6
	Consolidated Condensed Statements of Changes in Equity	7
	Consolidated Condensed Statements of Cash Flows	8
	Notes to Consolidated Condensed Financial Statements	9
Item 2.	Management's Discussion and Analysis of Financial Condition and Results of Operations	24
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	39
Item 4.	Controls and Procedures	39
PART II -	OTHER INFORMATION	
Item 1A.	Risk Factors	39
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	40
Item 5.	Other Information	40
Item 6.	Exhibits	41
	Signatures	42

PART I - FINANCIAL INFORMATION
ITEM 1. FINANCIAL STATEMENTS

FORTIVE CORPORATION AND SUBSIDIARIES
CONSOLIDATED CONDENSED BALANCE SHEETS
(\$ in millions, except share and per share amounts)

	As of	
	June 30, 2023 (unaudited)	December 31, 2022
ASSETS		
Current assets:		
Cash and equivalents	\$ 712.8	\$ 709.2
Trade accounts receivable less allowance for doubtful accounts of \$40.4 at June 30, 2023 and \$43.9 at December 31, 2022	935.2	958.5
Inventories:		
Finished goods	231.2	215.3
Work in process	105.2	96.4
Raw materials	224.8	225.0
Inventories	561.2	536.7
Prepaid expenses and other current assets	265.4	272.6
Total current assets	2,474.6	2,477.0
Property, plant and equipment, net of accumulated depreciation of \$789.2 at June 30, 2023 and \$754.5 at December 31, 2022	425.9	421.9
Other assets	474.3	455.8
Goodwill	9,051.9	9,048.5
Other intangible assets, net	3,304.0	3,487.4
Total assets	\$ 15,730.7	\$ 15,890.6
LIABILITIES AND EQUITY		
Current liabilities:		
Current portion of long-term debt	\$ 999.9	\$ 999.7
Trade accounts payable	585.6	623.0
Accrued expenses and other current liabilities	999.5	1,104.4
Total current liabilities	2,585.0	2,727.1
Other long-term liabilities	1,195.7	1,223.3
Long-term debt	1,978.2	2,251.6
Commitments and Contingencies (Note 8)		
Equity:		
Common stock: \$0.01 par value, 2.0 billion shares authorized; 362.7 million issued and 351.9 million outstanding at June 30, 2023; 361.5 million issued and 352.9 million outstanding at December 31, 2022	3.6	3.6
Additional paid-in capital	3,778.7	3,706.3
Treasury shares, at cost	(572.0)	(442.9)
Retained earnings	7,075.4	6,742.1
Accumulated other comprehensive loss	(319.9)	(325.7)
Total Fortive stockholders' equity	9,965.8	9,683.4
Noncontrolling interests	6.0	5.2
Total stockholders' equity	9,971.8	9,688.6
Total liabilities and equity	\$ 15,730.7	\$ 15,890.6

See the accompanying Notes to Consolidated Condensed Financial Statements.

FORTIVE CORPORATION AND SUBSIDIARIES
CONSOLIDATED CONDENSED STATEMENTS OF EARNINGS
(\$ and shares in millions, except per share amounts)
(unaudited)

	Three Months Ended		Six Months Ended	
	June 30, 2023	July 1, 2022	June 30, 2023	July 1, 2022
Sales of products and software	\$ 1,290.8	\$ 1,229.4	\$ 2,527.4	\$ 2,382.1
Sales of services	235.6	233.9	459.7	457.7
Total sales	1,526.4	1,463.3	2,987.1	2,839.8
Cost of product and software sales	(500.1)	(508.3)	(985.2)	(973.4)
Cost of service sales	(120.9)	(121.5)	(248.3)	(240.9)
Total cost of sales	(621.0)	(629.8)	(1,233.5)	(1,214.3)
Gross profit	905.4	833.5	1,753.6	1,625.5
Operating costs:				
Selling, general and administrative expenses	(514.0)	(484.9)	(1,021.7)	(965.5)
Research and development expenses	(100.1)	(100.1)	(200.2)	(199.2)
Russia exit and wind down costs	—	(16.2)	—	(16.2)
Operating profit	291.3	232.3	531.7	444.6
Non-operating income (expense), net:				
Interest expense, net	(33.1)	(21.0)	(65.2)	(39.8)
Other non-operating expense, net	(7.8)	(3.1)	(10.3)	(5.8)
Earnings before income taxes	250.4	208.2	456.2	399.0
Income taxes	(41.4)	(35.2)	(73.6)	(60.9)
Net earnings	\$ 209.0	\$ 173.0	\$ 382.6	\$ 338.1
Net earnings per share:				
Basic	\$ 0.59	\$ 0.48	\$ 1.08	\$ 0.94
Diluted	\$ 0.59	\$ 0.48	\$ 1.07	\$ 0.93
Average common stock and common equivalent shares outstanding:				
Basic	353.0	357.4	353.3	358.3
Diluted	355.5	359.8	356.0	364.2

See the accompanying Notes to Consolidated Condensed Financial Statements.

FORTIVE CORPORATION AND SUBSIDIARIES
CONSOLIDATED CONDENSED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)
(\$ in millions)
(unaudited)

	Three Months Ended		Six Months Ended	
	June 30, 2023	July 1, 2022	June 30, 2023	July 1, 2022
Net earnings	\$ 209.0	\$ 173.0	\$ 382.6	\$ 338.1
Other comprehensive income (loss), net of income taxes:				
Foreign currency translation adjustments	(7.4)	(118.6)	6.0	(158.0)
Pension adjustments	(0.2)	0.4	(0.2)	0.9
Total other comprehensive income (loss), net of income taxes	(7.6)	(118.2)	5.8	(157.1)
Comprehensive income	<u>\$ 201.4</u>	<u>\$ 54.8</u>	<u>\$ 388.4</u>	<u>\$ 181.0</u>

See the accompanying Notes to Consolidated Condensed Financial Statements.

FORTIVE CORPORATION AND SUBSIDIARIES
CONSOLIDATED CONDENSED STATEMENTS OF CHANGES IN EQUITY
(\$ and shares in millions)
(unaudited)

	Common Stock		Additional Paid-In Capital	Treasury Shares	Retained Earnings	Accumulated Other Comprehensive Loss	Noncontrolling Interests
	Shares Outstanding	Amount					
Balance, December 31, 2022	352.9	\$ 3.6	\$ 3,706.3	\$ (442.9)	\$ 6,742.1	\$ (325.7)	\$ 5.2
Net earnings for the period	—	—	—	—	173.6	—	—
Dividends to common shareholders	—	—	—	—	(24.7)	—	—
Other comprehensive income	—	—	—	—	—	13.4	—
Common stock-based award activity	0.8	—	36.3	—	—	—	—
Shares withheld for taxes	(0.2)	—	(12.1)	—	—	—	—
Change in noncontrolling interests	—	—	—	—	—	—	0.6
Balance, March 31, 2023	353.5	\$ 3.6	\$ 3,730.5	\$ (442.9)	\$ 6,891.0	\$ (312.3)	\$ 5.8
Net earnings for the period	—	—	—	—	209.0	—	—
Dividends to common shareholders	—	—	—	—	(24.6)	—	—
Other comprehensive income (loss)	—	—	—	—	—	(7.6)	—
Common stock-based award activity	0.5	—	52.3	—	—	—	—
Common stock repurchases	(2.0)	—	—	(129.1)	—	—	—
Shares withheld for taxes	(0.1)	—	(4.1)	—	—	—	—
Change in noncontrolling interests	—	—	—	—	—	—	0.2
Balance, June 30, 2023	351.9	\$ 3.6	\$ 3,778.7	\$ (572.0)	\$ 7,075.4	\$ (319.9)	\$ 6.0

	Common Stock		Additional Paid-In Capital	Treasury Shares	Retained Earnings	Accumulated Other Comprehensive Loss	Noncontrolling Interests
	Shares Outstanding	Amount					
Balance, December 31, 2021	359.1	\$ 3.6	\$ 3,670.0	\$ —	\$ 6,023.6	\$ (185.0)	\$ 4.8
Adoption of ASU 2020-06	—	—	(65.7)	—	62.8	—	—
Balance, January 1, 2022	359.1	\$ 3.6	\$ 3,604.3	—	\$ 6,086.4	\$ (185.0)	\$ 4.8
Net earnings for the period	—	—	—	—	165.1	—	—
Dividends to common shareholders	—	—	—	—	(25.1)	—	—
Other comprehensive income (loss)	—	—	—	—	—	(38.9)	—
Common stock-based award activity	0.5	—	23.8	—	—	—	—
Common stock repurchases	(1.0)	—	—	(63.8)	—	—	—
Shares withheld for taxes	(0.2)	—	(9.0)	—	—	—	—
Change in noncontrolling interest	—	—	—	—	—	—	0.5
Balance, April 1, 2022	358.4	\$ 3.6	\$ 3,619.1	\$ (63.8)	\$ 6,226.4	\$ (223.9)	\$ 5.3
Net earnings for the period	—	—	—	—	173.0	—	—
Dividends to common shareholders	—	—	—	—	(24.9)	—	—
Other comprehensive income	—	—	—	—	—	(118.2)	—
Common stock-based award activity	0.2	—	32.7	—	—	—	—
Common stock repurchases	(3.0)	—	—	(179.1)	—	—	—
Shares withheld for taxes	—	—	(0.6)	—	—	—	—
Change in noncontrolling interests	—	—	—	—	—	—	(0.2)
Balance, July 1, 2022	355.6	\$ 3.6	\$ 3,651.2	\$ (242.9)	\$ 6,374.5	\$ (342.1)	\$ 5.1

See the accompanying Notes to Consolidated Condensed Financial Statements.

FORTIVE CORPORATION AND SUBSIDIARIES
CONSOLIDATED CONDENSED STATEMENTS OF CASH FLOWS
(\$ in millions)
(unaudited)

	Six Months Ended	
	June 30, 2023	July 1, 2022
Cash flows from operating activities:		
Net earnings	\$ 382.6	\$ 338.1
Noncash items:		
Amortization	184.2	192.1
Depreciation	42.1	41.9
Stock-based compensation expense	55.7	45.0
Russia exit and wind down costs	—	9.2
Change in trade accounts receivable, net	26.0	(37.7)
Change in inventories	(27.4)	(50.7)
Change in trade accounts payable	(36.4)	40.1
Change in prepaid expenses and other assets	(13.1)	(39.2)
Change in accrued expenses and other liabilities	(118.3)	(29.6)
Net cash provided by operating activities	495.4	509.2
Cash flows from investing activities:		
Payments for additions to property, plant and equipment	(45.8)	(37.1)
Proceeds from sale of property	4.9	—
Cash paid for acquisitions, net of cash received	—	(1.6)
Net cash used in investing activities	(40.9)	(38.7)
Cash flows from financing activities:		
Net proceeds from (repayments of) commercial paper borrowings	(268.6)	481.3
Proceeds from borrowings (maturities greater than 90 days), net of issuance costs	—	397.0
Payment of 0.875% convertible senior notes due 2022	—	(1,156.5)
Repurchase of common shares	(129.1)	(242.9)
Payment of dividends	(49.3)	(50.0)
All other financing activities	5.6	(11.8)
Net cash used in financing activities	(441.4)	(582.9)
Effect of exchange rate changes on cash and equivalents	(9.5)	(24.0)
Net change in cash and equivalents	3.6	(136.4)
Beginning balance of cash and equivalents	709.2	819.3
Ending balance of cash and equivalents	\$ 712.8	\$ 682.9

See the accompanying Notes to Consolidated Condensed Financial Statements.

FORTIVE CORPORATION AND SUBSIDIARIES
NOTES TO CONSOLIDATED CONDENSED FINANCIAL STATEMENTS

NOTE 1. BUSINESS OVERVIEW

Fortive Corporation (“Fortive,” “the Company,” “we,” “us,” or “our”) is a provider of essential technologies for connected workflow solutions across a range of attractive end-markets. Our strategic segments - Intelligent Operating Solutions, Precision Technologies, and Advanced Healthcare Solutions - include well-known brands with leading positions in their markets. Our businesses design, develop, manufacture, and service professional and engineered products, software, and services, building upon leading brand names, innovative technologies, and significant market positions. Our research and development, manufacturing, sales, distribution, service, and administrative facilities are located in more than 50 countries around the world.

We prepared the unaudited consolidated condensed financial statements included herein in accordance with accounting principles generally accepted in the United States of America (“GAAP”) and the rules and regulations of the U.S. Securities and Exchange Commission (the “SEC”) applicable for interim periods. Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been omitted pursuant to such rules and regulations; however, we believe the disclosures are adequate to make the information presented not misleading. The unaudited consolidated condensed financial statements included herein should be read in conjunction with the audited annual consolidated financial statements as of and for the year ended December 31, 2022 and the footnotes (“Notes”) thereto included within our 2022 Annual Report on Form 10-K.

In our opinion, the accompanying financial statements contain all adjustments, which consist of only normal, recurring accruals necessary to fairly present our financial position, results of operations, comprehensive income, stockholders’ equity, and cash flows for the periods presented. The results of operations for the three and six months ended June 30, 2023, are not necessarily indicative of the results for the full year.

Russia Ukraine Conflict

In February 2022, Russian forces invaded Ukraine (“Russia Ukraine Conflict”) resulting in broad economic sanctions being imposed on Russia. In the second quarter of 2022, the Company exited business operations in Russia, other than for ASP’s sterilization products, which are exempt from international sanctions as humanitarian products.

In the three and six-month periods ended July 1, 2022, the Company recorded pre-tax charges of \$16.2 million primarily relating to the write-off of net assets, the write-off of the cumulative translation adjustment in earnings for legal entities deemed substantially liquidated, and to record provisions for employee severance and legal contingencies. These costs are identified as the “Russia exit and wind down costs” in the Condensed Consolidated Statements of Earnings. The exit activities were completed in 2022 and we did not incur additional charges in 2023.

Accumulated Other Comprehensive Loss

Foreign currency translation adjustments are generally not adjusted for income taxes as they relate to indefinite investments in non-U.S. subsidiaries. During the second quarter of 2022, our ¥14.4 billion Yen-denominated term loan and our €275 million Euro-denominated term loan were designated as net investment hedges of our investment in applicable foreign operations.

We recognized after-tax foreign currency transaction gains of \$5.1 million and \$3.6 million, respectively, during the three-month periods ended June 30, 2023 and July 1, 2022, and gains of \$3.4 million and \$3.6 million, respectively, during the six-month periods ended June 30, 2023 and July 1, 2022, on the debt that was deferred in the foreign currency translation component of Accumulated other comprehensive income (loss) (“AOCI”) as an offset to the foreign currency translation adjustments on our investments in foreign subsidiaries. Any amounts deferred in AOCI will remain until the hedged investment is sold or substantially liquidated. We recorded no ineffectiveness from our net investment hedges during the three and six-month periods ended June 30, 2023 and July 1, 2022.

The changes in AOCI by component are summarized below (\$ in millions):

	Foreign currency translation adjustments	Pension & post- retirement plan benefit adjustments ^(a)	Total
For the Three Months Ended June 30, 2023:			
Balance, March 31, 2023	\$ (288.0)	\$ (24.3)	\$ (312.3)
Other comprehensive income (loss) before reclassifications, net of income taxes	(7.4)	—	(7.4)
Amounts reclassified from accumulated other comprehensive income (loss):			
Increase (decrease)	—	(0.5) ^(b)	(0.5)
Income tax impact	—	0.3	0.3
Amounts reclassified from accumulated other comprehensive income (loss), net of income taxes	—	(0.2)	(0.2)
Net current period other comprehensive income (loss), net of income taxes	(7.4)	(0.2)	(7.6)
Balance, June 30, 2023	<u>\$ (295.4)</u>	<u>\$ (24.5)</u>	<u>\$ (319.9)</u>
For the Three Months Ended July 1, 2022:			
Balance, April 1, 2022	\$ (162.1)	\$ (61.8)	\$ (223.9)
Other comprehensive income (loss) before reclassifications, net of income taxes	(121.3)	—	(121.3)
Amounts reclassified from accumulated other comprehensive income (loss):			
Increase (decrease)	2.7	0.5 ^(b)	3.2
Income tax impact	—	(0.1)	(0.1)
Amounts reclassified from accumulated other comprehensive income (loss), net of income taxes	2.7	0.4	3.1
Net current period other comprehensive income (loss), net of income taxes	(118.6)	0.4	(118.2)
Balance, July 1, 2022	<u>\$ (280.7)</u>	<u>\$ (61.4)</u>	<u>\$ (342.1)</u>

	Foreign currency translation adjustments	Pension & post- retirement plan benefit adjustments ^(a)	Total
For the Six Months Ended June 30, 2023:			
Balance, December 31, 2022	\$ (301.4)	\$ (24.3)	\$ (325.7)
Other comprehensive income (loss) before reclassifications, net of income taxes	6.0	—	6.0
Amounts reclassified from accumulated other comprehensive income (loss):			
Increase (decrease)	—	(0.4) ^(b)	(0.4)
Income tax impact	—	0.2	0.2
Amounts reclassified from accumulated other comprehensive income (loss), net of income taxes	—	(0.2)	(0.2)
Net current period other comprehensive income (loss)	6.0	(0.2)	5.8
Balance, June 30, 2023	<u>\$ (295.4)</u>	<u>\$ (24.5)</u>	<u>\$ (319.9)</u>
For the Six Months Ended July 1, 2022:			
Balance, December 31, 2021	\$ (122.7)	\$ (62.3)	\$ (185.0)
Other comprehensive income (loss) before reclassifications, net of income taxes	(160.7)	—	(160.7)
Amounts reclassified from accumulated other comprehensive income (loss):			
Increase (decrease)	2.7	1.1 ^(b)	3.8
Income tax impact	—	(0.2)	(0.2)
Amounts reclassified from accumulated other comprehensive income (loss), net of income taxes	2.7	0.9	3.6
Net current period other comprehensive income (loss)	(158.0)	0.9	(157.1)
Balance, July 1, 2022	<u>\$ (280.7)</u>	<u>\$ (61.4)</u>	<u>\$ (342.1)</u>

^(a) Includes balances relating to defined benefit plans, supplemental executive retirement plans, and other postretirement employee benefit plans.

^(b) This component of AOCI is included in the computation of net periodic pension cost (refer to Note 12 in our most recently filed Form 10-K for additional details).

Allowances for Doubtful Accounts

All trade accounts and unbilled receivables are reported in the Consolidated Condensed Balance Sheets adjusted for any write-offs and net of allowances for credit losses. The allowances for credit losses represent management's best estimate of the credit losses expected from our unbilled and trade accounts receivable portfolios over the life of the underlying assets. Additions to the allowances are charged to current period earnings, amounts determined to be uncollectible are charged directly against the allowances, while amounts recovered on previously written-off accounts increase the allowances. During the three and six-month periods ending June 30, 2023 and July 1, 2022, the activity was immaterial.

Restructuring

We initiated a discrete plan in the first quarter of 2023 that is expected to be completed by December 31, 2023. The nature of these activities were broadly consistent throughout our segments and consist primarily of targeted workforce reductions in response to overall macroeconomic and other external conditions. We incurred these costs to position ourselves to provide superior products and services to customers in a cost-efficient manner, while taking into consideration the impact of broad economic uncertainties. During the three and six-month periods ended June 30, 2023, we incurred charges of \$10.7 million and \$28.3 million, respectively. These charges are included in Cost of sales and Selling, general, and administrative expenses in the Consolidated Condensed Statements of Earnings. Accrued restructuring costs were \$14.2 million as of June 30, 2023 and are included within Accrued expenses and other current liabilities in the Consolidated Condensed Balance Sheets. The total

restructuring charges we expect to recognize during the year ending December 31, 2023 under this discrete plan are approximately \$30 to \$35 million.

Convertible Senior Notes

On February 22, 2019, we issued \$1.4 billion in aggregate principal amount of our 0.875% Convertible Senior Notes due 2022 (“Convertible Notes”), including \$187.5 million in aggregate principal amount resulting from an exercise in full of an over-allotment option. The Convertible Notes were issued in a private placement to certain initial purchasers for resale to qualified institutional buyers pursuant to Rule 144A under the Securities Act. Upon conversion of the Convertible Notes, holders were entitled to receive cash, shares of our common stock, or a combination thereof, at our election. Upon adopting Accounting Standards Update No. 2020-06, *Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity* (“ASU 2020-06”), on January 1, 2022, we accounted for the Convertible Notes under the if-converted method in our calculation of diluted EPS, as required under the new guidance.

On February 15, 2022, the maturity date of the Convertible Notes, Fortive repaid, in cash, \$1.2 billion in outstanding principal and accrued interest thereon.

Recently Issued Accounting Standard

The Financial Accounting Standards Board (“FASB”) establishes changes to accounting principles under GAAP in the form of accounting standards updates (“ASUs”) to the Accounting Standards Codification (“ASC”). We consider the applicability and impact of all ASUs. Any recently issued ASUs were assessed and determined to be either not applicable or are expected to have an immaterial impact on the Company’s result of operations, financials position or cash flows.

NOTE 2. GOODWILL

The following is a roll forward of our carrying value of goodwill by segment (\$ in millions):

Balance,	Intelligent Operating Solutions	Precision Technologies	Advanced Healthcare Solutions	Total Goodwill
Balance, December 31, 2022	\$ 4,074.4	\$ 1,810.2	\$ 3,163.9	\$ 9,048.5
Foreign currency translation and other	13.5	(5.1)	(5.0)	3.4
Balance, June 30, 2023	<u>\$ 4,087.9</u>	<u>\$ 1,805.1</u>	<u>\$ 3,158.9</u>	<u>\$ 9,051.9</u>

NOTE 3. FAIR VALUE MEASUREMENTS

Accounting standards define fair value based on an exit price model, establish a framework for measuring fair value where our assets and liabilities are required to be carried at fair value, and provide for certain disclosures related to the valuation methods used within a valuation hierarchy as established within the accounting standards. This hierarchy prioritizes the inputs into three broad levels as follows:

- Level 1 inputs are quoted prices (unadjusted) for identical assets or liabilities in active markets.
- Level 2 inputs are quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets in markets that are not active, or other observable characteristics for the asset or liability, including interest rates, yield curves and credit risks, or inputs that are derived principally from, or corroborated by, observable market data through correlation.
- Level 3 inputs are unobservable inputs based on our assumptions. The classification of a financial asset or liability within the hierarchy is determined based on the lowest level input that is significant to the fair value measurement in its entirety.

Below is a summary of financial liabilities that are measured at fair value on a recurring basis (\$ in millions):

	Quoted Prices in Active Market (Level 1)	Significant Other Observable Inputs (Level 2)	Significant Unobservable Inputs (Level 3)	Total
June 30, 2023				
Deferred compensation liabilities	\$ —	\$ 37.5	\$ —	\$ 37.5
December 31, 2022				
Deferred compensation liabilities	—	31.5	—	31.5

Certain management employees participate in our nonqualified deferred compensation programs that permit such employees to defer a portion of their compensation, on a pretax basis, until after their termination of employment. All amounts deferred under such plans are unfunded, unsecured obligations and are included in Other long-term liabilities in the accompanying Consolidated Condensed Balance Sheets. Participants may choose among alternative earnings rates for the amounts they defer, which are primarily based on investment options within our defined contribution plans for the benefit of U.S. employees (except that the earnings rates for amounts contributed unilaterally by the Company are entirely based on changes in the value of Fortive common stock). Changes in the deferred compensation liability under these programs are recognized based on changes in the fair value of the participants' accounts and are recorded within Selling, general and administrative in the Consolidated Condensed Statements of Earnings.

Non-recurring Fair Value Measurements

Certain non-financial assets, primarily property, plant, and equipment, goodwill, and intangible assets, are not required to be measured at fair value on a recurring basis and are reported at their carrying value. However, these assets are required to be assessed for impairment whenever events or circumstances indicate that their carrying value may not be fully recoverable, and at least annually for goodwill and indefinite-lived intangible assets.

We evaluated events or circumstances that may indicate the carrying value of our non-financial assets may not be fully recoverable during the three and six-month periods ended June 30, 2023, and recorded no material impairments.

Fair Value of Financial Instruments

The carrying amount and fair value of financial instruments are as follows (\$ in millions):

	June 30, 2023		December 31, 2022	
	Carrying Amount	Fair Value	Carrying Amount	Fair Value
Current portion of long-term debt	\$ 999.9	\$ 1,000.0	\$ 999.7	\$ 1,000.0
Long-term debt, net of current maturities	1,978.2	1,824.4	2,251.6	2,078.1

As of June 30, 2023 and December 31, 2022, the current portion of long-term debt and long-term debt, net of current maturities were categorized as Level 1.

The fair values of long-term borrowings were based on quoted market prices. The difference between the fair value and the carrying amounts of long-term borrowings may be attributable to changes in market interest rates and/or our credit ratings subsequent to the borrowing. The fair value of cash and cash equivalents, trade accounts receivable, net, trade accounts payable, and commercial paper approximates their carrying value due to the short-term maturities of these instruments.

NOTE 4. FINANCING

The components of our debt were as follows (\$ in millions):

	June 30, 2023	December 31, 2022
U.S. dollar-denominated commercial paper	\$ 135.0	\$ 405.0
Delayed-Draw Term Loan due 2023	1,000.0	1,000.0
Euro Term Loan due 2025	300.0	294.4
Yen Term Loan due 2025	99.8	109.8
3.15% senior unsecured notes due 2026	900.0	900.0
4.30% senior unsecured notes due 2046	550.0	550.0
Long-term debt, principal amounts	2,984.8	3,259.2
Less: aggregate unamortized debt discounts, premiums, and issuance costs	6.7	7.9
Long-term debt, carrying value	2,978.1	3,251.3
Less: current portion of long-term debt	999.9	999.7
Long-term debt, net of current maturities	\$ 1,978.2	\$ 2,251.6

Refer to Note 11 of our 2022 Annual Report on Form 10-K for further details of our debt financing.

Other Liquidity Sources

We generally satisfy any short-term liquidity needs that are not met through operating cash flows and available cash primarily through issuances of commercial paper under our U.S. dollar and Euro-denominated commercial paper programs (“Commercial Paper Programs”). Under these programs, we may issue unsecured promissory notes with maturities not exceeding 397 and 183 days, respectively.

Interest expense on commercial paper is paid at maturity and is generally based on our credit ratings at the time of issuance and prevailing short-term interest rates.

The details of our outstanding Commercial Paper Programs as of June 30, 2023 were as follows (\$ in millions):

	Carrying value ^(a)	Annual effective rate	Weighted average maturity (in days)
U.S. dollar-denominated commercial paper	\$ 134.8	5.39 %	17

(a) Net of unamortized debt discount.

Credit support for the Commercial Paper Programs is provided by a five-year \$2.0 billion senior unsecured revolving credit facility that expires on October 18, 2027 (the “Revolving Credit Facility”) which, to the extent not otherwise providing credit support for our commercial paper programs, can also be used for working capital and other general corporate purposes. As of June 30, 2023, no borrowings were outstanding under the Revolving Credit Facility.

We classified our borrowings outstanding under the Commercial Paper Programs as Long-term debt in the accompanying Consolidated Condensed Balance Sheets as we had the intent and ability, as supported by availability under the Revolving Credit Facility, to refinance these borrowings for at least one year from the balance sheet date.

NOTE 5. SALES

We derive revenue primarily from the sale of products, including software, and services. Revenue is recognized when control of promised products or services is transferred to customers in an amount that reflects the consideration we expect to be entitled to in exchange for those products, software, or services.

Product sales include revenue from the sale of products and equipment, which includes our software and SaaS product offerings and equipment rentals. Service sales include revenues from extended warranties, post-contract customer support (“PCS”), maintenance contracts or services, contract labor to perform ongoing service at a customer location, services related to previously sold products, and software implementation services.

Contract Assets — In certain circumstances, we record contract assets which include unbilled amounts typically resulting from sales under contracts when revenue recognized exceeds the amount billed to the customer, and right to payment is not only

subject to the passage of time. Contract assets were \$97 million as of June 30, 2023 and \$82 million as of December 31, 2022. Contract assets are recorded in Prepaid expenses and other current assets in our Consolidated Condensed Balance Sheets.

Contract Costs — We incur and capitalize incremental costs to obtain certain contracts, typically sales-related commissions where the amortization period is greater than one year and costs associated with assets used by our customers in certain service arrangements. As of June 30, 2023 and December 31, 2022, we had \$48 million and \$42 million, respectively, in net revenue-related contract costs primarily related to certain software contracts. Revenue-related contract costs are recorded in the Prepaid expenses and other current assets and Other assets line items in our Consolidated Condensed Balance Sheets. These assets have estimated useful lives between three and five years.

Contract Liabilities — Our contract liabilities consist of deferred revenue generally related to subscription-based software contracts, PCS and extended warranty sales, where we generally receive up-front payment and recognize revenue over the service or support term. We classify deferred revenue as current or noncurrent based on the timing of when we expect to recognize revenue. The current portion of deferred revenue is included in Accrued expenses and other current liabilities and the noncurrent portion of deferred revenue is included in Other long-term liabilities in our Consolidated Condensed Balance Sheets.

Our contract liabilities consisted of the following (\$ in millions):

	June 30, 2023	December 31, 2022
Deferred revenue - current	\$ 495.4	\$ 509.6
Deferred revenue - noncurrent	41.5	38.0
Total contract liabilities	\$ 536.9	\$ 547.6

During the three and six-month periods ended June 30, 2023, we recognized revenue related to our contract liabilities at December 31, 2022 of \$113 million and \$288 million. The change in our contract liabilities from December 31, 2022 to June 30, 2023 was primarily due to the timing of billings and revenue recognized for subscription-based software contracts, PCS and extended warranty services.

Remaining Performance Obligations — Our remaining performance obligations represent the transaction price of firm, non-cancelable orders and the average contract value for software contracts, for which work has not been performed. We have excluded performance obligations with an original expected duration of one year or less from the amounts below.

The aggregate remaining performance obligations attributable to each of our segments is as follows (\$ in millions):

	June 30, 2023
Intelligent Operating Solutions	\$ 565.8
Precision Technologies	54.7
Advanced Healthcare Solutions	58.4
Total remaining performance obligations	\$ 678.9

The majority of remaining performance obligations are related to service and support contracts, which we expect to fulfill approximately 75 percent within the next two years, approximately 90 percent within the next three years, and substantially all within four years.

Disaggregation of Revenue

We disaggregate revenue from contracts with customers by sales of products and software and services, geographic location, and end market for each of our segments, as we believe it best depicts how the nature, amount, timing and uncertainty of our revenue and cash flows are affected by economic factors.

Disaggregation of revenue for the three-month period ended June 30, 2023 is presented as follows (\$ in millions):

	Total	Intelligent Operating Solutions	Precision Technologies	Advanced Healthcare Solutions
Sales:				
Sales of products and software	\$ 1,290.8	\$ 546.4	\$ 481.0	\$ 263.4
Sales of services	235.6	106.7	56.4	72.5
Total	<u>\$ 1,526.4</u>	<u>\$ 653.1</u>	<u>\$ 537.4</u>	<u>\$ 335.9</u>
Geographic:				
United States	\$ 827.8	\$ 362.0	\$ 273.2	\$ 192.6
China	178.9	58.6	94.1	26.2
All other (each country individually less than 5% of total sales)	519.7	232.5	170.1	117.1
Total	<u>\$ 1,526.4</u>	<u>\$ 653.1</u>	<u>\$ 537.4</u>	<u>\$ 335.9</u>
End markets:^(a)				
Direct sales:				
Healthcare	\$ 359.6	\$ 11.6	\$ 35.3	\$ 312.7
Industrial & Manufacturing	357.8	232.6	117.8	7.4
Utilities & Power	104.6	46.3	58.3	—
Government	132.9	77.2	47.0	8.7
Communications, Electronics & Semiconductor	97.4	23.3	73.4	0.7
Aerospace & Defense	76.3	0.2	76.1	—
Oil & Gas	71.6	67.6	4.0	—
Retail & Consumer	84.4	62.1	22.3	—
Other	181.6	100.1	81.5	—
Total direct sales	<u>1,466.2</u>	<u>621.0</u>	<u>515.7</u>	<u>329.5</u>
Distributors	60.2	32.1	21.7	6.4
Total	<u>\$ 1,526.4</u>	<u>\$ 653.1</u>	<u>\$ 537.4</u>	<u>\$ 335.9</u>

^(a) Direct sales by end market include sales made through third-party distributors where we have visibility into the end customer.

Disaggregation of revenue for the three-month period ended July 1, 2022 is presented as follows (\$ in millions):

	<u>Total</u>	<u>Intelligent Operating Solutions</u>	<u>Precision Technologies</u>	<u>Advanced Healthcare Solutions</u>
Sales:				
Sales of products and software	\$ 1,229.4	\$ 534.2	\$ 444.7	\$ 250.5
Sales of services	233.9	95.9	54.4	83.6
Total	<u>\$ 1,463.3</u>	<u>\$ 630.1</u>	<u>\$ 499.1</u>	<u>\$ 334.1</u>
Geographic:				
United States	\$ 779.0	\$ 341.1	\$ 249.6	\$ 188.3
China	182.7	56.1	101.6	25.0
All other (each country individually less than 5% of total sales)	501.6	232.9	147.9	120.8
Total	<u>\$ 1,463.3</u>	<u>\$ 630.1</u>	<u>\$ 499.1</u>	<u>\$ 334.1</u>
End markets:^(a)				
Direct sales:				
Healthcare	\$ 369.8	\$ 13.2	\$ 41.3	\$ 315.3
Industrial & Manufacturing	341.9	227.4	107.7	6.8
Utilities & Power	94.0	47.9	46.1	—
Government	110.1	60.5	41.4	8.2
Communications, Electronics & Semiconductor	102.1	26.3	75.4	0.4
Aerospace & Defense	64.7	0.2	64.5	—
Oil & Gas	68.6	65.8	2.8	—
Retail & Consumer	84.4	60.6	23.8	—
Other	158.5	90.1	68.4	—
Total direct sales	<u>1,394.1</u>	<u>592.0</u>	<u>471.4</u>	<u>330.7</u>
Distributors	69.2	38.1	27.7	3.4
Total	<u>\$ 1,463.3</u>	<u>\$ 630.1</u>	<u>\$ 499.1</u>	<u>\$ 334.1</u>

^(a) Direct sales by end market include sales made through third-party distributors where we have visibility into the end customer.

Disaggregation of revenue for the six-month period ended June 30, 2023 is presented as follows (\$ in millions):

	<u>Total</u>	<u>Intelligent Operating Solutions</u>	<u>Precision Technologies</u>	<u>Advanced Healthcare Solutions</u>
Sales:				
Sales of products and software	\$ 2,527.4	\$ 1,083.8	\$ 941.3	\$ 502.3
Sales of services	459.7	201.4	111.6	146.7
Total	<u>\$ 2,987.1</u>	<u>\$ 1,285.2</u>	<u>\$ 1,052.9</u>	<u>\$ 649.0</u>
Geographic:				
United States	\$ 1,599.3	\$ 702.1	\$ 524.5	\$ 372.7
China	360.3	123.5	186.3	50.5
All other (each country individually less than 5% of total sales)	1,027.5	459.6	342.1	225.8
Total	<u>\$ 2,987.1</u>	<u>\$ 1,285.2</u>	<u>\$ 1,052.9</u>	<u>\$ 649.0</u>
End markets:^(a)				
Direct sales:				
Healthcare	\$ 699.0	\$ 22.5	\$ 69.8	\$ 606.7
Industrial & Manufacturing	711.0	460.9	236.0	14.1
Utilities & Power	203.5	93.6	109.9	—
Government	244.0	139.0	87.9	17.1
Communications, Electronics & Semiconductor	203.3	48.9	153.0	1.4
Aerospace & Defense	143.9	0.3	143.6	—
Oil & Gas	141.9	133.5	8.4	—
Retail & Consumer	167.3	124.4	42.9	—
Other	351.7	195.1	156.6	—
Total direct sales	<u>2,865.6</u>	<u>1,218.2</u>	<u>1,008.1</u>	<u>639.3</u>
Distributors	121.5	67.0	44.8	9.7
Total	<u>\$ 2,987.1</u>	<u>\$ 1,285.2</u>	<u>\$ 1,052.9</u>	<u>\$ 649.0</u>

^(a) Direct sales by end market include sales made through third-party distributors where we have visibility into the end customer.

Disaggregation of revenue for the six-month period ended July 1, 2022 is presented as follows (\$ in millions):

	Total	Intelligent Operating Solutions	Precision Technologies	Advanced Healthcare Solutions
Sales:				
Sales of products and software	\$ 2,382.1	\$ 1,034.7	\$ 855.3	\$ 492.1
Sales of services	457.7	183.0	106.2	168.5
Total	\$ 2,839.8	\$ 1,217.7	\$ 961.5	\$ 660.6
Geographic:				
United States	\$ 1,518.9	\$ 663.0	\$ 483.6	\$ 372.3
China	328.1	104.0	170.9	53.2
All other (each country individually less than 5% of total sales)	992.8	450.7	307.0	235.1
Total	\$ 2,839.8	\$ 1,217.7	\$ 961.5	\$ 660.6
End markets:^(a)				
Direct sales:				
Healthcare	\$ 723.1	\$ 23.5	\$ 78.4	\$ 621.2
Industrial & Manufacturing	663.8	438.5	211.4	13.9
Utilities & Power	180.3	90.9	89.4	—
Government	215.8	112.1	86.1	17.6
Communications, Electronics & Semiconductor	189.9	50.1	138.8	1.0
Aerospace & Defense	120.1	0.3	119.8	—
Oil & Gas	133.4	128.1	5.3	—
Retail & Consumer	165.6	124.3	41.3	—
Other	312.4	177.6	134.7	0.1
Total direct sales	2,704.4	1,145.4	905.2	653.8
Distributors	135.4	72.3	56.3	6.8
Total	\$ 2,839.8	\$ 1,217.7	\$ 961.5	\$ 660.6

^(a) Direct sales by end market include sales made through third-party distributors where we have visibility into the end customer.

NOTE 6. INCOME TAXES

Our effective tax rates for the three and six-month period ended June 30, 2023 were 16.5% and 16.1%, respectively, as compared to 16.9% and 15.3%, respectively, for the three and six-month period ended July 1, 2022. The decrease in the effective tax rate for the three-month period ended June 30, 2023 as compared to the three-month period ended July 1, 2022 was primarily due to effect of Russia exit and wind down costs for which no tax benefit was recognized during the three-month period ending July 1, 2022. The increase in the effective tax rate for the six-month period ended June 30, 2023 as compared to the six-month period ended July 1, 2022 was primarily due to uncertain tax position reserves released during the six-month period ending July 1, 2022.

Our effective tax rates for the three and six-month periods ended June 30, 2023, differ from the U.S. federal statutory rate of 21% due primarily to the impact of credits and deductions provided by law and changes in our uncertain tax position reserves.

On August 16, 2022, the U.S. enacted the Inflation Reduction Act of 2022, which, among other provisions implements a 15% corporate alternative minimum tax. Based upon our current analysis of the Inflation Reduction Act of 2022 and subsequently released guidance, we believe the 15% corporate minimum tax will not have a material impact on our financial statements during 2023.

NOTE 7. STOCK-BASED COMPENSATION

The 2016 Stock Incentive Plan (the “Stock Plan”), provides for the grant of stock appreciation rights, restricted stock units, and performance stock units (collectively, “Stock Awards”), stock options, or any other stock-based award. As of June 30, 2023, approximately 14 million shares of our common stock were available for subsequent issuance under the Stock Plan. For a full description of our Stock Plan refer to Note 17 of our 2022 Annual Report on Form 10-K.

Stock-based Compensation Expense

Stock-based compensation has been recognized as a component of Selling, general and administrative expenses in the Consolidated Condensed Statements of Earnings based on the portion of the awards that are ultimately expected to vest.

The following summarizes the components of our stock-based compensation expense under the Stock Plan (\$ in millions):

	Three Months Ended		Six Months Ended	
	June 30, 2023	July 1, 2022	June 30, 2023	July 1, 2022
Stock Awards:				
Pretax compensation expense	\$ 19.9	\$ 16.0	\$ 38.0	\$ 28.7
Income tax benefit	(2.7)	(3.0)	(5.3)	(4.7)
Stock Award expense, net of income taxes	17.2	13.0	32.7	24.0
Stock options:				
Pretax compensation expense	9.1	9.1	17.7	16.3
Income tax benefit	(1.3)	(1.4)	(2.5)	(2.4)
Stock option expense, net of income taxes	7.8	7.7	15.2	13.9
Total stock-based compensation:				
Pretax compensation expense	29.0	25.1	55.7	45.0
Income tax benefit	(4.0)	(4.4)	(7.8)	(7.1)
Total stock-based compensation expense, net of income taxes	\$ 25.0	\$ 20.7	\$ 47.9	\$ 37.9

The following summarizes the unrecognized compensation cost for the Stock Plan awards as of June 30, 2023. This compensation cost is expected to be recognized over a weighted average period of approximately two years, representing the remaining service period related to the awards. Future compensation amounts will be adjusted for any changes in estimated forfeitures (\$ in millions):

Stock Awards	\$ 53.3
Stock options	121.5
Total unrecognized compensation cost	\$ 174.8

NOTE 8. COMMITMENTS AND CONTINGENCIES

For a description of our litigation and contingencies and additional information about our leases, refer to Note 16 and Note 10, respectively, in our 2022 Annual Report on Form 10-K.

Warranty

We generally accrue estimated warranty costs at the time of sale. In general, manufactured products are warranted against defects in material and workmanship when properly used for their intended purpose, installed correctly, and appropriately maintained. Warranty period terms depend on the nature of the product and range from 90 days up to the life of the product. The amount of the accrued warranty liability is determined based on historical information such as past experience, product failure rates or number of units repaired, estimated cost of material and labor, and, in certain instances, estimated property damage. The accrued warranty liability is reviewed on a quarterly basis and may be adjusted as additional information regarding expected warranty costs becomes known. During the six-month periods ending June 30, 2023 and July 1, 2022, warranty related activity was immaterial.

Leases

Operating lease cost for the three-month periods ended June 30, 2023 and July 1, 2022 was \$12 million and \$14 million, respectively. Operating lease costs for the six-month periods ended June 30, 2023 and July 1, 2022 was \$24 million and \$29 million, respectively. During the six-month periods ended June 30, 2023 and July 1, 2022, cash paid for operating leases included in operating cash flows was \$24 million and \$26 million, respectively. Right-of-use (“ROU”) assets obtained in exchange for operating lease obligations were \$18 million and \$6 million during the six-month periods ended June 30, 2023 and July 1, 2022, respectively. Operating lease ROU assets were \$158 million and \$162 million as of June 30, 2023 and December 31, 2022, respectively. Operating lease liabilities were \$166 million and \$169 million as of June 30, 2023 and December 31, 2022, respectively. Operating lease ROU assets and operating lease liabilities are reported on the Consolidated Condensed Balance Sheets within Other assets, Accrued expenses and Other current liabilities and Other long-term liabilities, respectively.

NOTE 9. NET EARNINGS PER SHARE

Basic net EPS is calculated by dividing net earnings attributable to common stockholders by the weighted average number of shares of common stock outstanding for the applicable period. Diluted EPS is similarly calculated, except that the calculation includes the dilutive effect of the assumed conversion of 0.875% Convertible Notes and associated issuance of shares under the if-converted method, while outstanding in 2022, and the assumed issuance of shares under stock-based compensation plans under the treasury stock method, except where the inclusion of such shares would have an anti-dilutive impact. Anti-dilutive options excluded from the diluted EPS calculation for both the three and six-month periods ended June 30, 2023 were 2.7 million, and were 7.7 million and 7.5 million for the three and six-month periods ended July 1, 2022, respectively.

Information related to the calculation of net earnings per share of common stock is summarized as follows (\$ and shares in millions, except per share amounts):

	Three Months Ended		Six Months Ended	
	June 30, 2023	July 1, 2022	June 30, 2023	July 1, 2022
Numerator				
Net earnings	\$ 209.0	\$ 173.0	\$ 382.6	\$ 338.1
Convertible note interest add-back (if converted method)	—	—	—	1.8
Diluted Net Earnings	\$ 209.0	\$ 173.0	\$ 382.6	\$ 339.9
Denominator				
Weighted average common shares outstanding used in basic earnings per share	353.0	357.4	353.3	358.3
Incremental common shares from:				
Assumed exercise of dilutive options and vesting of dilutive Stock Awards	2.5	2.4	2.7	2.7
Conversion of convertible notes (if converted method)	—	—	—	3.2
Weighted average common shares outstanding used in diluted earnings per share	355.5	359.8	356.0	364.2
Net earnings per common share - Basic	\$ 0.59	\$ 0.48	\$ 1.08	\$ 0.94
Net earnings per common share - Diluted	\$ 0.59	\$ 0.48	\$ 1.07	\$ 0.93

We declared and paid cash dividends per common share for the periods as presented below.

	Dividend Per Common Share	Amount (\$ in millions)
2023:		
First quarter	\$ 0.07	\$ 24.7
Second quarter	0.07	24.6
Total	\$ 0.14	\$ 49.3
2022:		
First quarter	\$ 0.07	\$ 25.1
Second quarter	0.07	24.9
Total	\$ 0.14	\$ 50.0

* The sum of the components of total dividends paid may not equal the total amount due to rounding.

Share Repurchase Program

On February 17, 2022, the Company's Board of Directors approved a share repurchase program authorizing the Company to repurchase up to 20 million shares of the Company's outstanding common stock from time to time on the open market or in privately negotiated transactions. There is no expiration date for the repurchase program, and the timing and amount of repurchases under the program are determined by the Company's management based on market conditions and other factors. The repurchase program may be suspended or discontinued at any time by the Board of Directors. During the three and six-month periods ended June 30, 2023, the Company purchased 2 million shares of its common stock at an average price of \$64.54. During the three and six-month periods ended July 1, 2022, the Company purchased 3 million and 4 million shares of its common stock at an average share price of \$59.71 and \$60.71, respectively. As of June 30, 2023, there were 11 million shares remaining for repurchase under the program.

NOTE 10. SEGMENT INFORMATION

We report our results in three separate business segments consisting of Intelligent Operating Solutions, Precision Technologies, and Advanced Healthcare Solutions. Our chief operating decision maker (“CODM”) assesses performance and allocates resources based on our operating segments, which are also our reportable segments.

Our Intelligent Operating Solutions segment provides advanced instrumentation, software and services to tens of thousands of customers enabling their mission-critical workflows. These offerings include electrical test & measurement, facility and asset lifecycle software applications, connected worker safety and compliance solutions across a range of vertical end markets, including manufacturing, process industries, healthcare, utilities and power, communications and electronics, among others.

Our Precision Technologies segment helps solve tough technical challenges to speed breakthroughs in a wide range of applications, from food and beverage production and manufacturing to next-generation electric vehicles and clean energy, as our customers seek new test solutions to enable the electrification and connectivity of everything. Our expertise in materials, methods and measurements are reflected in our electrical test & measurement, sensing and material technologies offered to a broad set of customers and vertical end markets, including industrial, power and energy, automotive, medical equipment, food and beverage, aerospace and defense, semiconductor, and other general industries.

Our Advanced Healthcare Solutions segment supplies critical workflow solutions enabling healthcare providers to deliver exceptional patient care more efficiently. Our offerings include instrument sterilization solutions, instrument tracking, cell therapy equipment design and manufacturing, biomedical test tools, radiation detection and safety monitoring, and end-to-end clinical productivity software and solutions. Our healthcare offerings help ensure critical safety standards are met, instruments and operating rooms are working at peak performance, and complex procedures are followed accurately in these mission-critical healthcare environments.

Our segment results are as follows (\$ in millions):

	Three Months Ended		Six Months Ended	
	June 30, 2023	July 1, 2022	June 30, 2023	July 1, 2022
Sales:				
Intelligent Operating Solutions	\$ 653.1	\$ 630.1	\$ 1,285.2	\$ 1,217.7
Precision Technologies	537.4	499.1	1,052.9	961.5
Advanced Healthcare Solutions	335.9	334.1	649.0	660.6
Total	\$ 1,526.4	\$ 1,463.3	\$ 2,987.1	\$ 2,839.8
Operating Profit:				
Intelligent Operating Solutions	\$ 161.7	\$ 129.9	\$ 295.2	\$ 236.9
Precision Technologies	136.3	115.3	259.0	216.7
Advanced Healthcare Solutions	25.9	28.1	42.2	56.1
Other	(32.6)	(24.8)	(64.7)	(48.9)
Russia exit and wind down costs	—	(16.2)	—	(16.2)
Total Operating Profit	291.3	232.3	531.7	444.6
Interest expense, net	(33.1)	(21.0)	(65.2)	(39.8)
Other non-operating expense, net	(7.8)	(3.1)	(10.3)	(5.8)
Earnings before income taxes	\$ 250.4	\$ 208.2	\$ 456.2	\$ 399.0

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Fortive Corporation ("Fortive," the "Company," "we," "us," or "our") is a provider of essential technologies for connected workflow solutions across a range of attractive end-markets. Our strategic segments - Intelligent Operating Solutions, Precision Technologies, and Advanced Healthcare Solutions - include well-known brands with leading positions in their markets. Our businesses design, develop, manufacture, and service professional and engineered products, software, and services, building upon leading brand names, innovative technologies, and significant market positions. We are headquartered in Everett, Washington and employ a team of more than 18,000 research and development, manufacturing, sales, distribution, service, and administrative employees in more than 50 countries around the world.

This Management's Discussion and Analysis of Financial Condition and Results of Operations ("MD&A") is designed to provide a reader of our financial statements with a narrative from the perspective of management. The following discussion should be read in conjunction with the MD&A and consolidated financial statements included in our 2022 Annual Report on Form 10-K. Our MD&A is divided into five sections:

- Information Relating to Forward-Looking Statements
- Overview
- Results of Operations
- Liquidity and Capital Resources
- Critical Accounting Estimates

INFORMATION RELATING TO FORWARD-LOOKING STATEMENTS

Certain statements included or incorporated by reference in this quarterly report, in other documents we file with or furnish to the Securities and Exchange Commission ("SEC"), in our press releases, webcasts, conference calls, materials delivered to shareholders and other communications, are "forward-looking statements" within the meaning of the United States federal securities laws. All statements other than historical factual information are forward-looking statements, including without limitation statements regarding: projections of revenue, expenses, profit, profit margins, tax rates, tax provisions, cash flows, pension and benefit obligations and funding requirements, our liquidity position or other financial measures; management's plans and strategies for future operations, including statements relating to anticipated operating performance, cost reductions, restructuring activities, new product and service developments, competitive strengths or market position, acquisitions, divestitures, strategic opportunities, securities offerings, stock repurchases, dividends and executive compensation; growth, declines and other trends in markets we sell into, including the expected impact of trade and tariff policies; new or modified laws, regulations and accounting pronouncements; impact of climate-related events or transition activities; outstanding claims, legal proceedings, tax audits and assessments and other contingent liabilities; foreign currency exchange rates and fluctuations in those rates; impact of changes to tax laws; general economic and capital markets conditions, including impact of inflation or interest rate changes; impact of geopolitical events, including the impact of Ukraine/Russia conflict and other hostilities; the timing of any of the foregoing; assumptions underlying any of the foregoing; and any other statements that address events or developments that we intend or believe will or may occur in the future. Terminology such as "believe," "anticipate," "should," "could," "intend," "will," "plan," "expect," "estimate," "project," "target," "may," "possible," "potential," "forecast" and "positioned" and similar references to future periods are intended to identify forward-looking statements, although not all forward-looking statements are accompanied by such words.

Forward-looking statements are based on assumptions and assessments made by our management in light of their experience and perceptions of historical trends, current conditions, expected future developments, and other factors they believe to be appropriate. Forward-looking statements are not guarantees of future performance and actual results may differ materially from the results, developments and business decisions contemplated by our forward-looking statements. Accordingly, you should not place undue reliance on any such forward-looking statements. Important factors that could cause actual results to differ materially from those envisaged in the forward-looking statements include, among others, the following:

Risk Related to Our Business Operations

- Conditions in the global economy, the markets we serve, and the financial markets and banking systems may adversely affect our business and financial statements.

- If we cannot adjust our manufacturing capacity, supply chain management or the purchases required for our manufacturing activities to reflect changes in market conditions, customer demand and supply chain or transportation disruptions, our profitability may suffer. In addition, our reliance upon sole or limited sources of supply for certain materials, components, and services could cause production interruptions, delays and inefficiencies.
- Our financial results are subject to fluctuations in the cost and availability of commodities or components that we use in our operations.
- Any resurgence in the spread of COVID-19 and the corresponding constraints on supply chain, labor force, and the operations of our customers, suppliers, and vendors could have an adverse impact on our business and results of operations.
- Our growth could suffer if the markets into which we sell our products and services decline, do not grow as anticipated, or experience cyclicality.
- We face intense competition and if we are unable to compete effectively, we may experience decreased demand and decreased market share. Even if we compete effectively, we may be required to reduce prices for our products and services.
- Our growth depends in part on the timely development and commercialization and customer acceptance of new and enhanced products and services based on technological innovation.
- If we are unable to recruit and retain key employees, our business may be harmed.
- A significant disruption in, or breach in security of, our information technology systems could adversely affect our business.
- Defects and unanticipated use or inadequate disclosure with respect to our products (including software) or services could adversely affect our business, reputation, and financial statements.
- Adverse changes in our relationships with, or the financial condition, performance, purchasing patterns, or inventory levels of, key distributors and other channel partners could adversely affect our financial statements.
- Our restructuring activities could have long-term adverse effects on our business.
- Work stoppages, works council campaigns, and other labor disputes could adversely impact our productivity and results of operations.
- If we suffer loss to our facilities, supply chains, distribution systems, or information technology systems due to catastrophe or other events, our operations could be seriously harmed.
- If we do not or cannot adequately protect our intellectual property, or if third parties infringe our intellectual property rights, we may suffer competitive injury or expend significant resources enforcing our rights.
- Third parties may claim that we are infringing or misappropriating their intellectual property rights and we could suffer significant litigation expenses, losses, or licensing expenses or be prevented from selling products or services.
- We are subject to a variety of litigation and other legal and regulatory proceedings in the course of our business that could adversely affect our financial statements.

Risk Related to our International Operations

- International economic, political, legal, compliance, and business factors could negatively affect our financial statements.
- Trade relations between China and the United States could have a material adverse effect on our business and financial statements.
- Foreign currency exchange rates, including the volatility thereof, may adversely affect our financial statements.

Risk Related to Our Acquisitions, Investments, and Dispositions

- Any inability to consummate acquisitions at our anticipated rate and at appropriate prices could negatively impact our growth rate and stock price.

- Our acquisition of businesses, joint ventures, and strategic relationships could negatively impact our financial statements.
- The indemnification provisions of acquisition agreements by which we have acquired companies may not fully protect us and as a result we may face unexpected liabilities.
- Divestitures or other dispositions could negatively impact our business, and contingent liabilities from businesses that we have sold could adversely affect our financial statements.
- Potential indemnification liabilities to Vontier Corporation (“Vontier”) pursuant to the separation agreement could materially and adversely affect our businesses, financial condition, results of operations, and cash flows.

Risk Related to Regulatory and Compliance Matters

- Changes in industry standards and governmental regulations may reduce demand for our products or services or increase our expenses.
- Our reputation, ability to do business, and financial statements may be impaired by improper conduct by any of our employees, agents, or business partners.
- Our operations, products, and services expose us to the risk of environmental, health, and safety liabilities, costs, and violations that could adversely affect our reputation and financial statements.
- Our businesses are subject to extensive regulation, including healthcare regulations; failure to comply with those regulations could adversely affect our financial statements and reputation.
- Climate change, or related governmental initiatives, including legal or regulatory measures, may negatively affect us.

Risk Related to Our Tax and Accounting Matters

- Changes in our effective tax rates or exposure to additional income tax liabilities or assessments could affect our profitability. In addition, audits by tax authorities could result in additional tax payments for prior periods.
- We could incur significant liability if our separation from Danaher, our separation of our Automation and Specialty business or our separation of Vontier (collectively, the “Separation Transactions”) are determined to be a taxable transaction.
- Changes in U.S. GAAP could adversely affect our reported financial results and may require significant changes to our internal accounting systems and processes.
- We may be required to recognize impairment charges for our goodwill and other intangible assets.

Risk Related to Our Financing Activities

- We have incurred a significant amount of debt, and our debt obligations, including the cost of such debt, will increase further if we incur additional debt and do not retire existing debt, our credit rating declines, or if the applicable interest rates rise.

See “Item 1A. Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2022 for further discussion regarding reasons that actual results may differ materially from the results, developments, and business decisions contemplated by our forward-looking statements. Forward-looking statements speak only as of the date of the report, document, press release, webcast, call, materials or other communication in which they are made (or such earlier date as may be specified in such statement). We do not assume any obligation to update or revise any forward-looking statement, whether as a result of new information, future events and developments or otherwise.

OVERVIEW

General

Fortive is a multinational business with global operations with approximately 46% of our sales derived from customers outside the United States in 2022. As a company with global operations, our businesses are affected by worldwide, regional, and industry-specific economic and political factors. Our geographic and industry diversity, as well as the range of products, software, and services we offer, typically help limit the impact of any one industry or the economy of any single country (except for the United States) on our operating results. Given the broad range of products manufactured, software and services provided, and geographies served, we do not use any indices other than general economic trends to predict the overall outlook for the Company. Our individual businesses monitor key competitors and customers, including their sales, to the extent possible, to gauge relative performance and the outlook for the future.

As a result of our geographic and industry diversity, we face a variety of opportunities and challenges, including technological development in most of the markets we serve, the expansion and evolution of opportunities in high-growth markets, trends and costs associated with a global labor force, and consolidation of our competitors. We define high-growth markets as developing markets of the world experiencing extended periods of accelerated growth in gross domestic product and infrastructure which include Eastern Europe, the Middle East, Africa, Latin America, and Asia with the exception of Japan and Australia. We operate in a highly competitive business environment in most markets, and our long-term growth and profitability will depend, in particular, on our ability to expand our business across geographies and market segments, identify, consummate, and integrate appropriate acquisitions, develop innovative and differentiated new products, services, and software, expand and improve the effectiveness of our sales force, continue to reduce costs and improve operating efficiency and quality, attract relevant talent and retain, grow, and empower our talented workforce, and effectively address the demands of an increasingly regulated environment. We are making significant investments, organically and through acquisitions, to address technological change in the markets we serve and to improve our manufacturing, research and development, and customer-facing resources in order to be responsive to our customers throughout the world.

Segment Presentation

We operate and report our results in three segments, Intelligent Operating Solutions, Precision Technologies, and Advanced Healthcare Solutions, each of which is further described below.

Our Intelligent Operating Solutions segment provides advanced instrumentation, software and services to tens of thousands of customers enabling their mission-critical workflows. These offerings include electrical test & measurement, facility and asset lifecycle software applications, connected worker safety and compliance solutions across a range of vertical end markets, including manufacturing, process industries, healthcare, utilities and power, communications and electronics, among others. Typical users of these safety, productivity and sustainability solutions include electrical engineers, electricians, electronic technicians, EHS professionals, network technicians, facility managers, first-responders, and maintenance professionals.

Our Precision Technologies segment helps solve tough technical challenges to speed breakthroughs in a wide range of applications, from food and beverage production and manufacturing to next-generation electric vehicles and clean energy, as our customers seek new test solutions to enable the electrification and connectivity of everything. Our expertise in materials, methods and measurements are reflected in our electrical test & measurement, sensing and material technologies offered to a broad set of customers and vertical end markets, including industrial, power and energy, automotive, medical equipment, food and beverage, aerospace and defense, semiconductor, and other general industries. Customers for these products and services include design engineers for advanced electronic devices and equipment, process and quality engineers focused on improved process capability and productivity, facility maintenance managers driving increased uptime, and other customers for whom precise measurement, reliability, and compliance are critical in their applications.

Our Advanced Healthcare Solutions segment supplies critical workflow solutions enabling healthcare providers to deliver exceptional patient care more efficiently. Our offerings include instrument sterilization solutions, instrument tracking, cell therapy equipment design and manufacturing, biomedical test tools, radiation detection and safety monitoring, and end-to-end clinical productivity software and solutions. Our healthcare offerings help ensure critical safety standards are met, instruments and operating rooms are working at peak performance, and complex procedures are followed accurately in these mission-critical healthcare environments.

Non-GAAP Measures

In this report, references to sales from existing businesses refer to sales from operations calculated according to generally accepted accounting principles in the United States (“GAAP”) but excluding (1) the impact from acquired and divested businesses and (2) the impact of currency translation. References to sales attributable to acquisitions or acquired businesses refer to GAAP sales from acquired businesses recorded prior to the first anniversary of the acquisition less the amount of sales attributable to certain divested businesses or product lines not considered discontinued operations prior to the first anniversary

of the divestiture. The portion of sales attributable to the impact of currency translation is calculated as the difference between (a) the period-to-period change in sales (excluding sales impact from acquired businesses) and (b) the period-to-period change in sales (excluding sales impact from acquired businesses) after applying the current period foreign exchange rates to the prior year period. Sales from existing businesses should be considered in addition to, and not as a replacement for or superior to, sales, and may not be comparable to similarly titled measures reported by other companies.

Management believes that reporting the non-GAAP financial measure of sales from existing businesses provides useful information to investors by helping identify underlying growth trends in our business and facilitating comparisons of our sales performance with our performance in prior and future periods and to our peers. We exclude the effect of acquisition and divestiture related items because the nature, size, and number of such transactions can vary dramatically from period to period and between us and our peers. We exclude the effect of currency translation from sales from existing businesses because the impact of currency translation is not under management's control and is subject to volatility. Management believes the exclusion of the effect of acquisitions and divestitures and currency translation may facilitate the assessment of underlying business trends and may assist in comparisons of long-term performance. References to sales volume from existing businesses refer to the impact of both price and unit sales.

Restructuring

We initiated a discrete plan in the first quarter of 2023 that is expected to be completed by December 31, 2023. The nature of these activities were broadly consistent throughout our segments and consist primarily of targeted workforce reductions in response to overall macroeconomic and other external conditions. We incurred these costs to position ourselves to provide superior products and services to customers in a cost-efficient manner, while taking into consideration the impact of broad economic uncertainties. During the three and six-month periods ended June 30, 2023, we incurred charges of \$10.7 million and \$28.3 million, respectively. These charges are included in Cost of sales and Selling, general, and administrative expenses in the Consolidated Condensed Statements of Earnings. Accrued restructuring costs were \$14.2 million as of June 30, 2023 and are included within Accrued expenses and other current liabilities in the Consolidated Condensed Balance Sheets. The total restructuring charges we expect to recognize during the year ending December 31, 2023 under this discrete plan are approximately \$30 to \$35 million.

Business Performance and Outlook

Business Performance For the Period Ended June 30, 2023

During the three and six-month periods ended June 30, 2023 (“the quarter” or the “second quarter” and “year-to-date period”, respectively), our sales increased by 4.3% and 5.2%, respectively. Year-over-year sales from existing businesses increased 5.5% and 7.1% during the second quarter and year-to-date period, respectively, reflecting favorable pricing, increased demand across many of our end markets and focused execution on service and delivery.

Geographically, in the second quarter, year-over-year sales from existing businesses in developed markets increased mid-single-digits, driven by high single-digit growth in North America and slight growth in Western Europe. Sales from existing businesses in high growth markets increased year-over-year in the second quarter at a low single-digit rate, driven by low single-digit growth in China and mid-twenties growth in India. In the year-to-date period, year-over-year sales from existing businesses in developed markets increased mid-single-digits, driven by mid-single-digit growth in both North America and Western Europe. Sales from existing businesses in high growth markets increased year-over-year in the year-to-date period at a low double-digit rate, driven by mid-teens growth in China, low-thirties growth in India, and mid-single-digit growth in Latin America.

Price increases contributed 5.0% and 4.8% to sales growth during the second quarter and year-to-date period, as compared to the comparable periods in 2022 and is reflected as a component of the change in sales from existing businesses. In both the second quarter and year-to-date period, price increases exceeded inflation impacts on purchased materials.

Despite lingering supply chain challenges which impacted our output in the second quarter and the year-to-date period, we have experienced an improvement in our operating results on a year-over-year basis. We continue to apply the Fortive Business System (“FBS”) to help mitigate the impact of these challenges and to serve our customers.

Outlook

We anticipate revenue growth to be between 3.5% and 4.5% for the third quarter of 2023, and 4.0% and 5.0% for the full 2023 year. We anticipate growth from existing businesses to be between 3.5% and 4.5% for the third quarter and 5.0% and 6.0% for the full year.

We expect foreign exchange rates to remain volatile throughout the year which could adversely impact our financial results in 2023. Additionally, our financial outlook is subject to various assumptions and risks, including but not limited to, macroeconomic conditions in the United States and other critical regions, ongoing challenges with global logistics and supply chains including the availability of electronic components, disruption in supply or transportation resulting from severe weather events or our vendors experiencing work stoppage from their unionized employees, impact of inflationary dynamics on our expenses or our ability to realize price increases in our sales, interest rates, market conditions in key product segments, and elective surgery rates. We will continue to deploy FBS to actively manage production challenges, collaborate with customers and suppliers to minimize disruptions and utilize pricing and other countermeasures to offset inflationary dynamics. We continue to monitor these conditions which may continue to impact our business, as well as potential adverse global economic trends and sentiments, monetary and fiscal policies, international trade and relations between the U.S., China and other nations, and investment and taxation policy initiatives being considered in the United States and by the Organization for Economic Co-operation and Development (“OECD”).

RESULTS OF OPERATIONS

Sales Growth

The following table summarizes total aggregate year-over-year sales growth and the components thereof for the second quarter as compared to the comparable period of 2022:

Components of Sales Growth

	% Change Three Months Ended June 30, 2023 vs. Comparable 2022 Period	% Change Six Months Ended June 30, 2023 vs. Comparable 2022 Period
Total revenue growth (GAAP)	4.3 %	5.2 %
Existing businesses (Non-GAAP)	5.5 %	7.1 %
Acquisitions and divestitures (Non-GAAP)	(0.3) %	(0.4) %
Currency exchange rates (Non-GAAP)	(0.9) %	(1.5) %

Operating Profit Margins

Operating profit margin was 19.1% for the second quarter, yielding an increase of 320 basis points as compared to 15.9% in the comparable period of 2022. Year-over-year changes in operating profit margin were comprised of the following:

- Year-over-year increase in price and sales volumes from existing businesses, gains from productivity measures and favorable foreign exchange rates, which were partially offset by unfavorable product mix, higher employee compensation and sales and marketing. — favorable 185 basis points
- The year-over-year effect of amortization from existing businesses offset by impairment of intangible assets — favorable 35 basis points
- The year-over-year net effect of acquisition-related transaction costs incurred in the second quarter of 2022 — favorable 55 basis points
- The year-over-year net effect of acquired and divested businesses, including amortization and acquisition-related fair value adjustments — favorable 5 basis points
- The year-over-year effect of costs relating to the discrete restructuring plan incurred in 2023 — unfavorable 70 basis points
- Russia exit and wind down costs which were incurred during the second quarter of 2022 — favorable 110 basis points

Operating profit margin was 17.8% for the year-to-date period ended June 30, 2023, an increase of 210 basis points as compared to 15.7% in the comparable period of 2022. Year-over-year changes in operating profit margin were comprised of the following:

- Year-over-year increase in price and sales volumes from existing businesses and gains from productivity measures, which were partially offset by higher employee compensation, unfavorable product mix, sales and marketing, and unfavorable foreign exchange rates — favorable 140 basis points
- The year-over-year effect of amortization from existing businesses offset by impairment of intangible assets — favorable 50 basis points
- The year-over-year net effect of acquisition-related transaction costs which were lower during the year-to-date period than those recognized during the comparable period in 2022 — favorable 55 basis points
- The year-over-year net effect of acquired and divested businesses, including amortization and acquisition-related fair value adjustments — favorable 5 basis points
- The year-over-year effect of costs relating to the discrete restructuring plan in 2023 — unfavorable 95 basis points
- Russia exit and wind down costs which were incurred during the year-to-date period of 2022 — favorable 55 basis points

Business Segments

Sales by business segment for each of the periods indicated were as follows (\$ in millions):

	Three Months Ended		Six Months Ended	
	June 30, 2023	July 1, 2022	June 30, 2023	July 1, 2022
Intelligent Operating Solutions	\$ 653.1	\$ 630.1	\$ 1,285.2	\$ 1,217.7
Precision Technologies	537.4	499.1	1,052.9	961.5
Advanced Healthcare Solutions	335.9	334.1	649.0	660.6
Total	\$ 1,526.4	\$ 1,463.3	\$ 2,987.1	\$ 2,839.8

INTELLIGENT OPERATING SOLUTIONS

Our Intelligent Operating Solutions segment provides advanced instrumentation, software and services to tens of thousands of customers enabling their mission-critical workflows. These offerings include electrical test & measurement, facility and asset lifecycle software applications, connected worker safety and compliance solutions across a range of vertical end markets, including manufacturing, process industries, healthcare, utilities and power, communications and electronics, among others.

Intelligent Operating Solutions Selected Financial Data

(\$ in millions)	Three Months Ended		Six Months Ended	
	June 30, 2023	July 1, 2022	June 30, 2023	July 1, 2022
Sales	\$ 653.1	\$ 630.1	\$ 1,285.2	\$ 1,217.7
Operating profit	161.7	129.9	295.2	236.9
Depreciation	8.5	9.1	16.9	18.6
Amortization	46.1	46.1	92.1	92.3
Operating profit as a % of sales	24.8 %	20.6 %	23.0 %	19.5 %
Depreciation as a % of sales	1.3 %	1.4 %	1.3 %	1.5 %
Amortization as a % of sales	7.1 %	7.3 %	7.2 %	7.6 %

Components of Sales Growth

	% Change Three Months Ended June 30, 2023 vs. Comparable 2022 Period	% Change Six Months Ended June 30, 2023 vs. Comparable 2022 Period
Total revenue growth (GAAP)	3.6 %	5.5 %
Existing businesses (Non-GAAP)	4.2 %	6.9 %
Currency exchange rates (Non-GAAP)	(0.6) %	(1.4) %

The sales results for both the second quarter and year-to-date period were driven by price increases, demand for gas detection equipment, software and service offerings in EHS and facility and asset lifecycle applications, partially offset by volume reductions in test and measurement instrumentation.

Geographically, sales from existing businesses in developed markets increased in the second quarter by mid-single-digits, driven by mid-single-digit growth in North America, slightly offset by mid-single-digit declines in Western Europe. Sales from existing businesses in high growth markets increased by mid-single-digits, driven by low double-digit growth in Asia, principally in China where sales were up by low double-digits, and partially offset by low double-digit declines in Latin America. On a year-to-date basis, sales from existing businesses in developed markets increased by mid-single-digits, driven by mid-single-digit growth in North America; Western Europe remained essentially flat. Sales from existing businesses in high growth markets increased year-over-year in the year-to-date period by mid-teens, on mid-twenties growth in Asia, principally in China where sales were up mid-twenties, and low twenties in the Middle East.

Price increases contributed 5.2% and 5.4% to sales growth during the second quarter and year-to-date period, as compared to the comparable periods of 2022, and is reflected as a component of the change in sales from existing businesses.

Operating profit margin increased 420 basis points during the second quarter as compared to the comparable period of 2022. Year-over-year changes in operating profit margin were comprised of the following:

- Year-over-year increase in price from existing businesses, gains from productivity measures and favorable foreign exchange rates, partially offset by higher employee compensation costs and volume reductions — favorable 420 basis points
- The year-over-year effect of amortization from existing businesses offset by impairments of intangible assets — unfavorable 15 basis points
- The year-over-year net effect of acquisition-related transaction costs, which were incurred in the second quarter of 2022 — favorable 85 basis points
- The year-over-year effect of costs relating to the discrete restructuring plan in 2023 — unfavorable 70 basis points

Operating profit margin increased 350 basis points during the year-to-date period, as compared to the comparable period of 2022. Year-over-year operating profit margin comparisons were comprised of the following:

- Year-over-year increases in price and sales volume from existing businesses, and gains from productivity measures, partially offset by higher employee compensation costs — favorable 360 basis points
- The year-over-year effect of amortization from existing businesses offset by impairment of intangible assets — favorable 20 basis points
- The year-over-year net effect of acquisition-related transaction costs, which were incurred during the year-to-date period in 2022 — favorable 95 basis points
- The year-over-year effect of costs relating to the discrete restructuring plan in 2023 — unfavorable 125 basis points

PRECISION TECHNOLOGIES

Our Precision Technologies segment helps solve tough technical challenges to speed breakthroughs in a wide range of applications, from food and beverage production and manufacturing to next-generation electric vehicles and clean energy, as our customers seek new test solutions to enable the electrification and connectivity of everything. Our expertise in materials, methods and measurements are reflected in our electrical test & measurement, sensing and material technologies offered to a broad set of customers and vertical end markets, including industrial, power and energy, automotive, medical equipment, food and beverage, aerospace and defense, semiconductor, and other general industries.

Precision Technologies Selected Financial Data

(\$ in millions)	Three Months Ended		Six Months Ended	
	June 30, 2023	July 1, 2022	June 30, 2023	July 1, 2022
Sales	\$ 537.4	\$ 499.1	\$ 1,052.9	\$ 961.5
Operating profit	136.3	115.3	259.0	216.7
Depreciation	6.6	6.2	12.6	12.2
Amortization	0.4	3.6	1.5	7.2
Operating profit as a % of sales	25.4 %	23.1 %	24.6 %	22.5 %
Depreciation as a % of sales	1.2 %	1.2 %	1.2 %	1.3 %
Amortization as a % of sales	0.1 %	0.7 %	0.1 %	0.7 %

Components of Sales Growth

	% Change Three Months Ended June 30, 2023 vs. Comparable 2022 Period	% Change Six Months Ended June 30, 2023 vs. Comparable 2022 period
Total revenue growth (GAAP)	7.7 %	9.5 %
Existing businesses (Non-GAAP)	8.4 %	11.0 %
Currency exchange rates (Non-GAAP)	(0.7) %	(1.5) %

The sales results for both the second quarter and year-to-date period were driven by price increases across the segment and volume increases with test and measurement products and energetic materials, partially offset by a volume reduction in sensing technologies.

Geographically, sales from existing businesses in developed markets increased by low double-digits in the second quarter, driven by low double-digit growth in both North America and Western Europe. Sales from existing businesses in high growth markets increased by low single-digit in the second quarter driven by high twenties growth in India and mid-teens growth in Latin America, partially offset by a slight decline in Asia, principally due to a mid-single-digit decline in China. On a year-to-date basis, sales from existing businesses in developed markets increased by low double-digits, driven by high single-digit growth in North America and low double-digit growth in Western Europe. Sales from existing businesses in high growth markets increased year-over-year in the year-to-date period by mid-teens, driven by low double-digit growth in Asia, led by China with low double-digit growth, and low thirties growth in India.

Price increases in our Precision Technologies segment contributed 5.8% and 5.4% to sales growth for the second quarter and year-to-date period, respectively, as compared to the comparable periods of 2022, and is reflected as a component of the change in sales from existing businesses.

Operating profit margin increased 230 basis points for the second quarter as compared to the comparable period of 2022. Year-over-year changes in operating profit margin were comprised of the following:

- Year-over-year increase in price and sales volume from existing businesses and gains from productivity measures, partially offset by higher employee compensation costs — favorable 190 basis points
- The year-over-year effect of amortization from existing businesses — favorable 65 basis points
- The year-over-year effect of costs relating to the discrete restructuring plan in 2023 — unfavorable 25 basis points

Operating profit margin increased 210 basis points during the year-to-date period as compared to the comparable period of 2022. Year-over-year operating profit margins were comprised of the following:

- Year-over-year increase in price and sales volume from existing businesses, gains from productivity measures, and spending reductions, all partially offset by higher employee compensation costs, and unfavorable exchange rates — favorable 190
- The year-over-year effect of amortization from existing businesses — favorable 60
- The year-over-year effect of costs relating to the discrete restructuring plan in 2023 — unfavorable 40 basis points

ADVANCED HEALTHCARE SOLUTIONS

Our Advanced Healthcare Solutions segment supplies critical workflow solutions enabling healthcare providers to deliver exceptional patient care more efficiently. Our offerings include instrument sterilization solutions, instrument tracking, cell therapy equipment design and manufacturing, biomedical test tools, radiation detection and safety monitoring, and end-to-end clinical productivity software and solutions. Our healthcare offerings help ensure critical safety standards are met, instruments and operating rooms are working at peak performance, and complex procedures are followed accurately in these mission-critical healthcare environments.

Advanced Healthcare Solutions Financial Data

(\$ in millions)	Three Months Ended		Six Months Ended	
	June 30, 2023	July 1, 2022	June 30, 2023	July 1, 2022
Sales	\$ 335.9	\$ 334.1	\$ 649.0	\$ 660.6
Operating profit	25.9	28.1	42.2	56.1
Depreciation	5.4	4.7	10.5	9.4
Amortization	45.3	46.1	90.6	92.6
Operating profit as a % of sales	7.7 %	8.4 %	6.5 %	8.5 %
Depreciation as a % of sales	1.6 %	1.4 %	1.6 %	1.4 %
Amortization as a % of sales	13.5 %	13.8 %	14.0 %	14.0 %

Components of Sales Growth

	% Change Three Months Ended June 30, 2023 vs. Comparable 2022 period	% Change Six Months Ended June 30, 2023 vs. Comparable 2022 Period
Total revenue growth (GAAP)	0.6 %	(1.8) %
Existing businesses (Non-GAAP)	3.5 %	1.8 %
Acquisitions and divestitures (Non-GAAP)	(1.5) %	(1.6) %
Currency exchange rates (Non-GAAP)	(1.4) %	(2.0) %

The sales results for the second quarter were driven by price increases and slightly higher volume with gains in sterilization and quality assurance products, dosimetry services and software offerings being offset by declines in system design and related services. The sales results for the year-to-date period were driven by price increases and demand increases for dosimetry and software and related services, which were partially offset by volume declines in sterilization and quality assurance products and system design services.

Geographically, sales from existing businesses in developed markets increased by mid-single-digits in the second quarter primarily due to mid-single-digit growth in North America partially offset by mid-single-digit declines in Western Europe. In high growth markets, sales from existing businesses increased by low single-digits in the second quarter, driven by high-teens growth in Latin America and low double-digit growth in China, partially offset by a low double-digit decline in the rest of Asia. On a year-to-date basis, sales from existing businesses in developed markets increased by low single-digits, driven by low single-digit growth in North America and high single-digit growth in Japan, partially offset by a slight decline in Western Europe. Sales from existing businesses in high growth markets declined by low single-digits, driven by mid-teens growth in Latin America and a low single-digit increase in China, both were more than offset by a low double-digit decline in the rest of Asia and high-teens declines in Eastern Europe driven by the exit from Russia last year.

Price increases in our Advanced Healthcare Solutions segment contributed 3.4% and 2.8% to sales growth during the second quarter and year-to-date period, respectively, as compared to the comparable periods of 2022, and is reflected as a component of the change in sales from existing businesses.

Operating profit margin decreased 70 basis points during the quarter, as compared to the comparable period of 2022. Year-over-year changes in operating profit margin were comprised of the following:

- Year-over-year increases in price from existing businesses and gains from productivity measures were more than offset by unfavorable product mix, higher employee compensation and material costs, and higher sales and marketing costs — unfavorable 65 basis points
- The year-over-year effect of amortization from existing businesses — favorable 30 basis points
- The year-over-year net effect of acquisition-related transaction costs which were incurred in the second quarter of 2022 — favorable 80 basis points
- The year-over-year effect of divested businesses, including amortization, and acquisition-related fair value adjustments to inventory — favorable 15 basis points
- The year-over-year effect of costs relating to the discrete restructuring plan in 2023 — unfavorable 130 basis points

Operating profit margin decreased 200 basis points during the year-to-date period as compared to the comparable period of 2022. Year-over-year changes in operating profit margin were comprised of the following:

- Year-over-year increase in price from existing businesses and gains from productivity measures was more than offset by reductions in volume, unfavorable product mix, higher employee compensation and material costs, sales and marketing costs and unfavorable changes in foreign exchange rates — unfavorable 180 basis points
- The year-over-year effect of amortization from existing businesses — favorable 5 basis points
- The year-over-year net effect of acquisition-related transaction costs which were incurred in the year-to-date period of 2022 — favorable 60 basis points
- The year-over-year effect of divested businesses, including amortization, and acquisition-related fair value adjustments to inventory — favorable 30 basis points
- The year-over-year effect of costs relating to the discrete restructuring plan in 2023 — unfavorable 115 basis points

COST OF SALES AND GROSS PROFIT

(\$ in millions)	Three Months Ended		Six Months Ended	
	June 30, 2023	July 1, 2022	June 30, 2023	July 1, 2022
Sales	\$ 1,526.4	\$ 1,463.3	\$ 2,987.1	\$ 2,839.8
Cost of sales	(621.0)	(629.8)	(1,233.5)	(1,214.3)
Gross profit	\$ 905.4	\$ 833.5	\$ 1,753.6	\$ 1,625.5
Gross profit margin	59.3 %	57.0 %	58.7 %	57.2 %

The year-over-year increase in gross profit during the second quarter and year-to-date period, as compared to the comparable periods of 2022, is due primarily to year-over-year increases in price and sales volumes, productivity measures and FBS initiatives, partially offset by unfavorable product mix, higher employee compensation costs, and restructuring charges. The year-to-date period was also impacted by unfavorable changes in foreign currency exchange rates.

OPERATING EXPENSES

(\$ in millions)	Three Months Ended		Six Months Ended	
	June 30, 2023	July 1, 2022	June 30, 2023	July 1, 2022
Sales	\$ 1,526.4	\$ 1,463.3	\$ 2,987.1	\$ 2,839.8
Selling, general and administrative (“SG&A”)	514.0	484.9	1,021.7	965.5
Research and development (“R&D”)	100.1	100.1	200.2	199.2
Russia exit and wind down costs	—	16.2	—	16.2
SG&A as a % of sales	33.7 %	33.1 %	34.2 %	34.0 %
R&D as a % of sales	6.6 %	6.8 %	6.7 %	7.0 %

SG&A increased during the second quarter and year-to-date period, as compared to the comparable periods of 2022 due to increased employee compensation expenses, customer acquisition and marketing costs, restructuring costs partially offset by savings from productivity measures.

R&D, consisting principally of internal and contract engineering personnel costs, was flat in the second quarter and increased slightly during the year-to-date period, as compared to the comparable periods of 2022 due to ongoing investment in innovation and key initiatives and higher employee compensation costs.

RUSSIA EXIT AND WIND DOWN COSTS

In the three and six-month periods ended July 1st, 2022, we incurred pre-tax costs totaling \$16.2 million in the second quarter, for the write-off of net assets, the cumulative translation adjustment in earnings for legal entities deemed substantially liquidated, and to record provisions for employee severance and legal contingencies. Of the \$16.2 million incurred, approximately \$9.2 million represents non-cash charges and is reflected as such in the Consolidated Condensed Statement of Cash Flows. The costs were primarily related to our segments, as follows: Intelligent Operating Solutions \$13.8 million, Precision Technologies \$2.2 million and Advanced Healthcare Solutions \$1.3 million. The exit activities were completed in 2022 and we did not incur additional charges in 2023.

INTEREST COSTS

For a discussion of our outstanding indebtedness, refer to Note 4 to the consolidated condensed financial statements.

Net interest expense for the second quarter and year-to-date period was \$33 million and \$65 million as compared to \$21 million and \$40 million in the comparable periods in 2022. The year-over-year increase in interest expense was due to higher interest rates incurred on floating rate debt instruments, despite overall lower debt balances.

INCOME TAXES

Our effective tax rates for the three and six-month period ended June 30, 2023 were 16.5% and 16.1%, respectively, as compared to 16.9% and 15.3%, respectively, for the three and six-month period ended July 1, 2022. The decrease in the effective tax rate for the three-month period ended June 30, 2023 as compared to the three-month period ended July 1, 2022 was primarily due to effect of Russia exit and wind down costs for which no tax benefit was recognized during the three-month period ending July 1, 2022. The increase in the effective tax rate for the six-month period ended June 30, 2023 as compared to the six-month period ended July 1, 2022 was primarily due to uncertain tax position reserves released during the six-month period ending July 1, 2022.

Our effective tax rates for the three and six-month periods ended June 30, 2023, differ from the U.S. federal statutory rate of 21% due primarily to the impact of credits and deductions provided by law and changes in our uncertain tax position reserves.

On August 16, 2022, the U.S. enacted the Inflation Reduction Act of 2022, which, among other provisions implements a 15% corporate alternative minimum tax. Based upon our current analysis of the Inflation Reduction Act of 2022 and subsequently released guidance, we believe the 15% corporate minimum tax will not have a material impact on our financial statements during 2023.

COMPREHENSIVE INCOME

Comprehensive income increased by \$147 million during the second quarter as compared to the comparable period in 2022 due primarily to favorable changes in foreign currency translation adjustments of \$111 million, and an increase in net income.

Comprehensive income increased by \$207 million during the year-to-date period as compared to the comparable period in 2022 due primarily to favorable changes in foreign currency translation adjustments of \$164 million, and an increase in net income.

LIQUIDITY AND CAPITAL RESOURCES

We assess our liquidity in terms of our ability to generate cash to fund our operating, investing, and financing activities. We generate substantial cash from operating activities and believe that our operating cash flow and other sources of liquidity, which consist of available cash, our revolving credit facility, and access to commercial paper, bank loans, and capital markets, will be sufficient to allow us to continue funding and investing in our existing businesses, consummate strategic acquisitions, make interest and principal payments on our outstanding indebtedness, fulfill our contractual obligations, and manage our capital structure on a short and long-term basis.

We have generally satisfied any short-term liquidity needs that are not met through operating cash flows and available cash through issuances of commercial paper under our U.S. dollar and Euro-denominated commercial paper programs (“Commercial Paper Programs”).

Credit support for the Commercial Paper Programs is provided by a five-year \$2.0 billion senior unsecured revolving credit facility that expires on October 18, 2027 (the “Revolving Credit Facility”) which, to the extent not otherwise providing credit support for the commercial paper programs, can also be used for working capital and other general corporate purposes. As of June 30, 2023, no borrowings were outstanding under the Revolving Credit Facility.

The availability of the Revolving Credit Facility as a standby liquidity facility to repay maturing commercial paper is an important factor in maintaining the existing credit ratings of the Commercial Paper Programs when we have outstanding borrowings. We expect to limit any future borrowings under the Revolving Credit Facility to amounts that would leave sufficient credit available under the facility to allow us to borrow, if needed, and repay any outstanding commercial paper as it matures.

On June 7, 2023, we filed with the SEC an “automatic shelf” registration statement (the “Shelf Registration Statement”). Under the Shelf Registration Statement, we may from time to time sell shares of common stock, preferred stock, debt securities, depositary shares, purchase contracts, purchase units, warrants and subscription rights in one or more offerings.

We continue to monitor the financial markets, the stability of U.S and international banks and general global economic conditions. If changes in financial markets or other areas of the economy adversely affect our access to the capital markets and other financing sources, we would expect to rely on a combination of available cash and existing available capacity under our credit facilities to provide short-term funding.

Overview of Cash Flows and Liquidity

Following is an overview of our cash flows and liquidity (\$ in millions):

(\$ in millions)	Six Months Ended	
	June 30, 2023	July 1, 2022
Net cash provided by operating activities	\$ 495.4	\$ 509.2
Payments for additions to property, plant and equipment	\$ (45.8)	\$ (37.1)
Proceeds from sale of property	4.9	—
Cash paid for acquisitions, net of cash received	—	(1.6)
Net cash used in investing activities	\$ (40.9)	\$ (38.7)
Net proceeds from (repayments of) commercial paper borrowings	\$ (268.6)	\$ 481.3
Proceeds from borrowings (maturities greater than 90 days), net of issuance costs	—	397.0
Payment of 0.875% convertible senior notes due 2022	—	(1,156.5)
Repurchase of common shares	(129.1)	(242.9)
Payment of dividends	(49.3)	(50.0)
All other financing activities	5.6	(11.8)
Net cash used in financing activities	\$ (441.4)	\$ (582.9)

Operating Activities

Cash flows from operating activities can fluctuate significantly from period-to-period as working capital needs and the timing of payments for income taxes, interest, pension funding, and other items impact reported cash flows.

Operating cash flows were \$495 million during the year-to-date period, representing a decrease of \$14 million, or 2.7%, as compared to the comparable period of 2022. The year-over-year change in operating cash flows was primarily attributable to the following factors:

- Year-over-year increases of \$38 million in Operating cash flows from net earnings, net of non-cash items (Amortization, Depreciation, Stock-based compensation, and Russia exit and wind down costs incurred 2022).
- The aggregate changes in trade accounts receivable, inventories, and trade accounts payable used \$38 million of cash during the quarter as compared to using \$48 million in the comparable period of 2022. The amount of cash flow generated from or used by the aggregate of trade accounts receivable, inventories, and trade accounts payable depends upon how effectively we manage the cash conversion cycle, which generally represents the number of days that elapse from the day we pay for the purchase of raw materials and components to the collection of cash from our customers, and can be significantly impacted by the timing of collections and payments in a period.
- The aggregate changes in prepaid expenses, other assets, accrued expenses and other liabilities used \$131 million of cash in the year-to-date period as compared to using \$69 million of cash in the comparable period of 2022. The year-over-year changes were driven by timing differences related to contract liabilities, tax payments, and employee compensation and benefits.

Investing Activities

Cash outflows from investing activities, consisting primarily of capital expenditures, increased \$2 million during the year-to-date period, as compared to the comparable period of 2022. The increase in investing cash flows was primarily due to a year-over-year increase in capital expenditures of approximately \$9 million, partially offset by proceeds from sales of property.

Capital expenditures are made primarily for increasing production capacity, replacing aged equipment, supporting product development initiatives for hardware and software offerings, improving information technology systems, and purchasing equipment that is used in revenue arrangements with customers. For the current year, we expect capital spending to be approximately \$90-110 million, although actual expenditures will ultimately depend on business conditions.

Financing Activities and Indebtedness

Cash flows from financing activities consist primarily of cash flows associated with the issuance and repayment of debt and commercial paper, payments of cash dividends to shareholders and share repurchases.

In the year-to-date period, financing activities used cash of \$441 million, reflecting the following transactions:

- Incurred \$269 million in net commercial paper repayments under the U.S. dollar-denominated commercial paper program, which had a weighted annual effective rate of 5.39% and a weighted average maturity of approximately 17 days.
- As of June 30, 2023, we repurchased 2 million shares of our common stock for approximately \$129 million under our share repurchase program.
- Dividend payments to common shareholders totaling \$49 million.

In the comparable 2022 period, financing activities used cash of \$583 million, reflecting the following transaction:

- On June 17, 2022, we entered into a three-year ¥14.4 billion senior unsecured facility yielding net proceeds of approximately \$107 million.
- On June 21, 2022, we entered into a three-year €275 million senior unsecured facility yielding net proceeds of approximately \$290 million.
- Incurred \$481 million in net commercial paper borrowings under the U.S. dollar-denominated commercial paper program, which had a weighted annual effective rate of 1.84% and a weighted average remaining maturity of approximately 32 days.
- Repurchased 4 million shares for approximately \$243 million under our share repurchase program.
- Made dividend payments to common shareholders totaling \$50 million.
- On February 15, 2022, the maturity date of the Convertible Notes, Fortive repaid, in cash, \$1.2 billion in outstanding principal and accrued interest thereon.

Refer to Note 4 of the consolidated condensed financial statements for additional information regarding our financing activities and indebtedness.

Cash and Cash Requirements

As of June 30, 2023, we held approximately \$713 million of cash and equivalents that were invested in highly liquid investment-grade instruments with a maturity of 90 days or less and yielded insignificant interest income during the year-to-date period. Approximately 91% of the \$713 million in cash and equivalents was held outside of the United States.

We have cash requirements to support working capital needs, capital expenditures and acquisitions, pay interest and service debt, pay taxes and any related interest or penalties, fund our pension plans as required, pay dividends to shareholders, and support other business needs or objectives. With respect to our cash requirements, we generally intend to use available cash and internally generated funds to meet these cash requirements, but in the event that additional liquidity is required, particularly in connection with acquisitions and repayment of maturing debt, we may also borrow under our commercial paper programs or credit facilities or enter into new credit facilities and either borrow directly thereunder or use such credit facilities to backstop additional borrowing capacity under our commercial paper programs. We also may from time to time access the capital markets, including to take advantage of favorable interest rate environments or other market conditions.

Foreign cumulative earnings remain subject to foreign remittance taxes. We have made an election regarding the amount of earnings that we do not intend to repatriate due to local working capital needs, local law restrictions, high foreign remittance costs, previous investments in physical assets and acquisitions, or future growth needs. For most of our foreign operations, we make an assertion regarding the amount of earnings in excess of intended repatriation that are expected to be held for indefinite reinvestment. No provisions for foreign remittance taxes have been made with respect to earnings that are planned to be reinvested indefinitely. The amount of foreign remittance taxes that may be applicable to such earnings is not readily determinable given local law restrictions that may apply to a portion of such earnings, unknown changes in foreign tax law that may occur during the applicable restriction periods caused by applicable local corporate law for cash repatriation, and the various tax planning alternatives we could employ if we repatriated these earnings.

As of June 30, 2023, we expect to have sufficient liquidity to satisfy our cash needs for the foreseeable future.

CRITICAL ACCOUNTING ESTIMATES

There were no material changes during the three and six-month periods ended June 30, 2023 to the items we disclosed as our critical accounting estimates in “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our 2022 Annual Report on Form 10-K.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Our concentrations of credit risk arising from trade receivables is limited due to the diversity of our customers. Our businesses perform credit evaluations of their customers’ financial conditions as appropriate and also obtain collateral or other security when appropriate.

Additional quantitative and qualitative disclosures about market risk appear in “Management’s Discussion and Analysis of Financial Condition and Results of Operations — Financial Instruments and Risk Management,” in our 2022 Annual Report on Form 10-K. There were no material changes during the three and six-month periods ended June 30, 2023 to the information reported in our 2022 Annual Report on Form 10-K relating to our evaluation of interest rate, foreign currency exchange, and commodity price risk. Refer to Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations for discussion around the impact of these items in the first quarter.

ITEM 4. CONTROLS AND PROCEDURES

Our management, with the participation of the President and Chief Executive Officer, and the Senior Vice President and Chief Financial Officer, has evaluated the effectiveness of our disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”)) as of the end of the period covered by this report. Based on such evaluation, the President and Chief Executive Officer, and the Senior Vice President and Chief Financial Officer, have concluded that, as of the end of such period, these disclosure controls and procedures were effective.

There have been no changes in our internal control over financial reporting (as such term is defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) that occurred during the most recent completed fiscal quarter that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II - OTHER INFORMATION

ITEM 1A. RISK FACTORS

Information regarding risk factors appears in “Management’s Discussion and Analysis of Financial Condition and Results of Operations - Information Relating to Forward-Looking Statements,” in Part I - Item 2 of this Form 10-Q and in the “Risk Factors” section of our 2022 Annual Report on Form 10-K. There were no material changes during the quarter and year-to-date period ended June 30, 2023 to the risk factors reported in the “Risk Factors” section of our 2022 Annual Report on Form 10-K.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

On February 17, 2022, the Company's Board of Directors approved a share repurchase program authorizing the Company to repurchase up to 20 million shares of the Company's outstanding common stock from time to time on the open market or in privately negotiated transactions, with 11 million shares remaining authorized under the share repurchase program as of June 30, 2023. There is no expiration date for the repurchase program, and the timing and amount of repurchases under the program are determined by the Company's management based on market conditions and other factors. The repurchase program may be suspended or discontinued at any time by the Board of Directors. During the year-to-date period ended June 30, 2023, the Company purchased 2 million shares of its common stock at an average price of \$64.54. As of June 30, 2023, there were 11 million shares remaining for repurchase under the program.

The following table provides details about our share repurchases during the fiscal quarter ended June 30, 2023.

Period	Total number of shares (or units) purchased	Average price paid per share (or unit)	Total number of shares (or units) purchased as part of publicly announced plans or programs	Maximum number (or approximate dollar value) of shares (or units) that may yet be purchased under the plans or programs
Apr 2 - Apr 30	—	\$ —	N/A	N/A
May 1 - May 31	2,000,000	64.54	2,000,000	11,000,000
June 1 - June 30	—	—	N/A	N/A
Total	2,000,000	\$ 64.54	2,000,000	11,000,000

ITEM 5. OTHER INFORMATION**(c) Trading Plans**

During the second quarter ended June 30, 2023, none of the Company's directors or Section 16 officers adopted or terminated any "Rule 10b5-1 trading arrangement" or any "non-Rule 10b5-1 trading arrangement," as each term is defined in Item 408(a) of Regulation S-K.

ITEM 6. EXHIBITS

<u>Exhibit Number</u>	<u>Description</u>
3.1	Restated Certificate of Incorporation of Fortive Corporation (incorporated by reference to Exhibit 3.1 to Fortive Corporation's Quarterly Report on Form 10-Q for the fiscal quarter ended July 1, 2022, File No. 1-37654).
3.2	Amended and Restated Bylaws of Fortive Corporation (incorporated by reference from Exhibit 3.1 to Fortive Corporation's Current Report on Form 8-K, filed on November 8, 2022 (Commission File No. 1-37654).
10.1	Description of Compensation Arrangements for Non-Management Directors*
31.1	Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2	Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1	Certification of Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
32.2	Certification of Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101.INS	XBRL Instance Document (1) - the instance document does not appear in the Interactive Data File because XBRL tags are embedded within the Inline XBRL document.
101.SCH	Inline XBRL Taxonomy Extension Schema Document (1)
101.CAL	Inline XBRL Taxonomy Extension Calculation Linkbase Document (1)
101.DEF	Inline XBRL Taxonomy Extension Definition Linkbase Document (1)
101.LAB	Inline XBRL Taxonomy Extension Label Linkbase Document (1)
101.PRE	Inline XBRL Taxonomy Extension Presentation Linkbase Document (1)
104	The cover page from this Quarterly Report on Form 10-Q for the quarter ended June 30, 2023, formatted in Inline XBRL and contained in Exhibit 101

* Indicates management contract or compensatory plan, contract or arrangement

- (1) Exhibit 101 to this report includes the following documents formatted in Inline XBRL (Extensible Business Reporting Language): (i) Consolidated Condensed Balance Sheets as of June 30, 2023 and December 31, 2022, (ii) Consolidated Condensed Statements of Earnings for the three and six-month periods ended June 30, 2023 and July 1, 2022, (iii) Consolidated Condensed Statements of Comprehensive Income for the three and six-month periods ended June 30, 2023 and July 1, 2022, (iv) Consolidated Condensed Statement of Changes in Equity for the three and six-month periods ended June 30, 2023 and July 1, 2022, (v) Consolidated Condensed Statements of Cash Flows for the six-month periods ended June 30, 2023 and July 1, 2022, and (vi) Notes to Consolidated Condensed Financial Statements.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

FORTIVE CORPORATION:

Date: July 26, 2023

By: /s/ Charles E. McLaughlin
Charles E. McLaughlin
Senior Vice President and Chief Financial Officer

Date: July 26, 2023

By: /s/ Christopher M. Mulhall
Christopher M. Mulhall
Chief Accounting Officer

FORTIVE CORPORATION DIRECTOR COMPENSATION POLICY

Each non-management director receives:

- An annual retainer of \$105,000 (the “Annual Base Retainer”), payable, based upon election (the “Payment Election”) of such director under the terms of the Fortive Corporation Non-Employee Director’s Deferred Compensation Plan, as may be amended from time to time (“DCP”), in cash (the “Cash Base Retainer”) equal to the Annual Base Retainer amount, in a RSU grant (the “Equity Base Retainer”) with a target award value of the Annual Base Retainer amount, or in a combination of Cash Base Retainer and Equity Base Retainer, with the allocation between Cash Base Retainer and Equity Base Retainer determined based on the Payment Election.
- In addition to any Equity Retainer (as defined below), an annual equity award with a target award value of \$200,000 (the “Annual Equity Grant”), with 75% allocated to RSUs and 25% to options. The options are fully vested as of the grant date. The RSU component of the Annual Equity Grant shall vest upon the earlier of (1) the first anniversary of the grant date, or (2) the date of, and immediately prior to, the next annual meeting of Fortive shareholders following the grant date with the underlying shares issued and delivered upon vesting.
- Reimbursement for Fortive-related out-of-pocket expenses, including travel expenses.

In addition, the Board chair receives:

- An annual retainer of \$92,500 (the “Annual Board Chair Retainer”), payable, based upon the Payment Election, in cash (“Cash Board Chair Retainer”) equal to the Annual Board Chair Retainer amount, in an annual RSU grant (the “Equity Board Chair Retainer”) with a target award value of the Annual Board Chair Retainer amount, or in a combination of Cash Board Chair Retainer and Equity Board Chair Retainer, with the allocation between Cash Board Chair Retainer and Equity Board Chair Retainer determined based on the Payment Election.
- An annual equity award with a target value of \$92,500 (divided equally between options and RSUs or comprised solely of RSUs, in each case, as described above for the Annual Equity Grant).

Furthermore, the chair of the Audit Committee receives an annual retainer of \$25,000 (the “Annual AC Chair Retainer”), the chair of the Compensation Committee receives an annual retainer of \$20,000 (the “CC Chair Retainer”), the chair of the Nominating and Governance Committee receives an annual retainer of \$20,000 (the “NGC Chair Retainer”), and the chair of the Finance Committee receives an annual retainer of \$10,000 (together with the AC Chair Retainer, the CC Chair Retainer, and the NGC Chair Retainer, the “Annual Committee Chair Retainers”), which Annual Committee Chair Retainers are payable, based upon the Payment Election, in cash (“Cash Committee Chair Retainer”) equal to the corresponding Annual Committee Chair Retainer amount, in a RSU grant (“Equity Committee Chair Retainer”) with a target award value of the Annual Committee Chair Retainer amount, or in a combination of Cash Committee Chair Retainer and Equity Committee Chair Retainer, with the allocation

between Cash Committee Chair Retainer and Equity Committee Chair Retainer determined based on the Payment Election.

Moreover, each non-chair member of the Audit Committee receives an annual retainer of \$15,000 (the "AC Member Retainer"), each non-chair member of the Compensation Committee receives an annual retainer of \$10,000 (the "CC Member Retainer"), each non-chair member of the Finance Committee receives an annual retainer of \$10,000 (the "FC Member Retainer"), and each non-chair member of the Nominating and Governance Committee receives an annual retainer of \$10,000 (together with the AC Member Retainer, the CC Member Retainer, and the FC Member Retainer, the "Annual Member Retainer"), which Annual Member Retainers are payable, based upon the Payment Election, in cash ("Cash Member Retainer" and, together with the Cash Base Retainer, the Cash Board Chair Retainer, and the Cash Committee Chair Retainer, the "Cash Retainer") equal to the corresponding Annual Member Retainer amount, in a RSU grant ("Equity Member Retainer" and, together with the Equity Base Retainer, the Equity Board Chair Retainer, and the Equity Committee Chair Retainer, the "Equity Retainer") with a target award value of the Annual Member Retainer amount, or in a combination of Cash Member Retainer and Equity Member Retainer, with the allocation between Cash Member Retainer and Equity Member Retainer determined based on the Payment Election.

The Annual Base Retainer, the Annual Board Chair Retainer, the Annual Committee Chair Retainers, and the Annual Member Retainers are referred to collectively as the "Annual Retainer."

A director will make a single Payment Election that will govern the director's entire Annual Retainer.

The foregoing notwithstanding, any Annual Board Chair Retainer, Annual Committee Chair Retainers, and/or Annual Member Retainers that become determined as to a director after the time of an Annual Equity Grant to such director shall be payable in cash until the next Annual Equity Grant notwithstanding any contrary Payment Election by such director.

All Cash Retainers will be paid in four, equal installments following each quarter of service, with any amendments or adjustments to such Cash Retainer effective the quarter following such amendment or adjustment.

If applicable, the grant of the Equity Retainer will be made concurrently with the corresponding Annual Equity Grant; provided that the Equity Retainer shall vest upon the earlier of (1) the first anniversary of the corresponding grant date, or (2) the date of, and immediately prior to, the next annual meeting of Fortive shareholders following such grant date, but the underlying shares shall not be issued until the earlier to occur of (i) the director's death, or (ii) the date elected by such director in the corresponding Payment Election, which selected payment date shall not be earlier than the first day of the seventh month following the director's Separation from Service from the Board.

Certification

I, James A. Lico, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of Fortive Corporation;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
 - a. designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 - b. designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 - c. evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
 - d. disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
 - a. all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
 - b. any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: July 26, 2023

By: /s/ James A. Lico
James A. Lico
President and Chief Executive Officer

Certification

I, Charles E. McLaughlin, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of Fortive Corporation;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
 - a. designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 - b. designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 - c. evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
 - d. disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
 - a. all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
 - b. any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: July 26, 2023

By: /s/ Charles E. McLaughlin
Charles E. McLaughlin
Senior Vice President and Chief Financial Officer

**CERTIFICATION OF CHIEF EXECUTIVE OFFICER
PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

I, James A. Lico, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge, Fortive Corporation's Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2023 fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and that information contained in such Quarterly Report on Form 10-Q fairly presents in all material respects the financial condition and results of operations of Fortive Corporation.

Date: July 26, 2023

By: /s/ James A. Lico

James A. Lico

President and Chief Executive Officer

This certification accompanies the Quarterly Report on Form 10-Q pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and shall not be deemed filed for purposes of Section 18 of the Exchange Act, or otherwise subject to the liability of that section. This certification shall not be deemed to be incorporated by reference into any filing under the Securities Act or the Exchange Act, except to the extent that Fortive Corporation specifically incorporates it by reference.

**CERTIFICATION OF CHIEF FINANCIAL OFFICER
PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

I, Charles E. McLaughlin, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge, Fortive Corporation's Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2023 fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and that information contained in such Quarterly Report on Form 10-Q fairly presents in all material respects the financial condition and results of operations of Fortive Corporation.

Date: July 26, 2023

By: /s/ Charles E. McLaughlin

Charles E. McLaughlin

Senior Vice President and Chief Financial Officer

This certification accompanies the Quarterly Report on Form 10-Q pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and shall not be deemed filed for purposes of Section 18 of the Exchange Act, or otherwise subject to the liability of that section. This certification shall not be deemed to be incorporated by reference into any filing under the Securities Act or the Exchange Act, except to the extent that Fortive Corporation specifically incorporates it by reference.